-
1Academic Journal
Source: Пролиферативный синдром в биологии и медицине.
Subject Terms: adverse drug reactions, macrolides, макролиды, фармакогенетика, персонализированная медицина, НЛР, personalized medicine, нежелательные лекарственные реакции, ADRs, 3. Good health, pharmacogenetics
-
2Academic Journal
Source: Biomedical Chemistry: Research and Methods; Vol. 8 No. 4 (2025): Online first; e00303 ; Biomedical Chemistry: Research and Methods; Том 8 № 4 (2025): Принято в печать; e00303 ; 2618-7531
Subject Terms: in silico studies, estimating atomic contributions, structural fragments, molecular targets, adverse drug reactions, in silico исследования, оценка вклада атомов, структурные фрагменты, молекулярные мишени, нежелательные лекарственные реакции
File Description: application/pdf
Availability: http://www.bmc-rm.org/index.php/BMCRM/article/view/303
-
3Academic Journal
Source: Russian Journal of Child Neurology; Vol 19, No 4 (2024); 29-41 ; Русский журнал детской неврологии; Vol 19, No 4 (2024); 29-41 ; 2412-9178 ; 2073-8803
Subject Terms: selective serotonin reuptake inhibitors, adverse drug reaction, cardiotoxicity, long QT interval syndrome, torsade de pointes, ventricular tachycardia, sudden cardiac death, селективные ингибиторы обратного захвата серотонина, нежелательные лекарственные реакции, кардиотоксичность, синдром удлиненного интервала QT, пируэтная тахикардия, желудочковая тахикардия, синдром внезапной смерти
File Description: application/pdf
Relation: https://rjdn.abvpress.ru/jour/article/view/494/339; https://rjdn.abvpress.ru/jour/article/view/494
-
4Academic Journal
Authors: G. I. Syraeva, A. S. Kolbin, S. A. Mishinova, A. A. Kalyapin
Source: Качественная клиническая практика, Vol 0, Iss 3, Pp 19-30 (2022)
Subject Terms: фармаконадзор, RS1-441, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, фармакоэкономика, Medical technology, нестероидные противовоспалительные средства, нежелательные лекарственные реакции, R855-855.5, автоматизированная информационная система росздравнадзора, ddd, 3. Good health
-
5Academic Journal
Source: Качественная клиническая практика, Vol 0, Iss 2, Pp 55-68 (2022)
Subject Terms: лекарственно-индуцированное внутримозговое кровоизлияние, селективные ингибиторы обратного захвата серотонина, 3. Good health, RS1-441, 03 medical and health sciences, статины, Pharmacy and materia medica, 0302 clinical medicine, тромболитические препараты, Medical technology, антиагреганты, нежелательные лекарственные реакции, R855-855.5, внутримозговое кровоизлияние, антикоагулянты
-
6Academic Journal
Authors: A. P. Pereverzev, O. D. Ostroumova
Source: Качественная клиническая практика, Vol 0, Iss 4, Pp 60-74 (2022)
Subject Terms: лекарственно-индуцированные заболевания, RS1-441, 03 medical and health sciences, лекарственные средства, Pharmacy and materia medica, 0302 clinical medicine, Medical technology, сердечная недостаточность, нежелательные лекарственные реакции, R855-855.5, безопасность, 3. Good health
-
7Academic Journal
Authors: G. I. Syraeva, A. S. Kolbin
Source: Качественная клиническая практика, Vol 0, Iss 4, Pp 16-26 (2022)
Subject Terms: фармаконадзор, RS1-441, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, Medical technology, нестероидные противовоспалительные средства, нежелательные лекарственные реакции, R855-855.5, автоматизированная информационная система росздравнадзора, 3. Good health
-
8Academic Journal
Authors: M. S. Cherniaeva, M. A. Rozhkova, M. V. Kazakova, L. A. Egorova, O. M. Maslennikova, G. S. Lebedev, N. V. Lomakin, D. A. Sychev, М. С. Черняева, М. А. Рожкова, М. В. Казакова, Л. А. Егорова, О. М. Масленникова, Г. С. Лебедев, Н. В. Ломакин, Д. А. Сычев
Source: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 17, No 3 (2024); 384-395 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 17, No 3 (2024); 384-395 ; 2070-4933 ; 2070-4909
Subject Terms: пожилые пациенты, adverse drug reactions, ADRs, potentially inappropriate medicinal, PIMs, elderly patients, нежелательные лекарственные реакции, НЛР, потенциально не рекомендованные лекарственные средства, ПНР ЛС
File Description: application/pdf
Relation: https://www.pharmacoeconomics.ru/jour/article/view/1047/563; https://www.pharmacoeconomics.ru/jour/article/downloadSuppFile/1047/115; 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023; 71 (7): 2052–81. https://doi.org/10.1111/jgs.18372.; Beers M., Ouslande J., Rollingher I., et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991; 151 (9): 1825–32.; Beers M. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med. 1997; 157 (14): 1531–6.; Fick D.,Cooper J.,Wade W., et al. Updating the Beers criteria for potentially inappropri ate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003; 163 (22): 2716–24. https://doi.org/10.1001/archinte.163.22.2716.; American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012; 60 (4): 616–31. https://doi.org/10.1111/j.1532-5415.2012.03923.x.; American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015; 63 (11): 2227–46. https://doi.org/10.1111/jgs.13702.; 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019; 67 (4): 674–94. https://doi.org/10.1111/jgs.15767.; Сычев Д.А., Черняева М.С., Рожкова М.А., Воробьева А.Е. Потенциально не рекомендованные лекарственные средства для применения у пациентов пожилого возраста: критерии Бирса (рекомендации Американского гериатрического общества 2023 г.). Безопасность и риск фармакотерапии. 2024. https://doi.org/10.30895/2312-7821-2024-420.; Lee G., Lim J., Page A., et al. Applicability of explicit potentially inappropriate medication lists to the Australian context: a systematic review. Australas J Ageing. 2022; 41 (2): 200–21. https://doi.org/10.1111/ajag.13038.; Niwata S., Yamada Y., Ikegami N. Prevalence of inappropriate medication using Beers criteria in Japanese long-term care facilities. BMC Geriatr. 2006; 6: 1. https://doi.org/10.1186/1471-2318-6-1.; Василенко В.В. Критерии Бирса. Новости медицины и фармации: интернетиздание. URL: http://www.mif-ua.com/archive/article/14054 (дата обращения 20.05.2024).; Сычев Д.А., Данилина К.С., Отделенов В.А. Клинико-фармакологические подходы к решению проблемы полипрагмазии у пожилых пациентов в условиях многопрофильного стационара. Клиническая фармакология и терапия. 2013; 22 (2): 87–92.; Сычев Д.А., Данилина К.С., Головина О.В. Частота назначения потенциально не рекомендованных препаратов (по критериям Бирса) пожилым пациентам, находящимся в терапевтических отделениях многопрофильного стационара. Терапевтический архив. 2015; 87 (1): 27–30. https://doi.org/10.17116/terarkh201587127-30.; Краснова Н.М., Сычев Д.А., Венгеровский А.И., Александрова Т.Н. Современные методы оптимизации фармакотерапии у пожилых пациентов в условиях многопрофильного стационара. Клиническая медицина. 2017; 95 (11): 1042-49. https://doi.org/10.18821/0023-2149-2017-95-11-1042-1049.; Ильина Е.С., Сычев Д.А., Богова О.Т. Падение пациента старческого возраста, связанное с применением бензодиазепиновых транквилизаторов: клиническое наблюдение. Медико-социальная экспертиза и реабилитация. 2017; 20 (2): 104–6. https://doi.org/10.18821/1560-9537-2017-20-2-104-106.; Малыхин Ф.Т., Батурин В.А. Оценка назначения потенциально нерекомендуемых лекарственных препаратов пульмонологическим пациентам пожилого и старческого возраста. Медицина. 2017; 1: 19–24.; Зурдинова А.А., Шараева А.Т., Сатыбалдиева А.Т. Фармакоэпидемиологический анализ применения лекарственных средств при лечении пациентов пожилого возраста. Вестник Кыргызско-Российского Славянского университета. 2018; 18 (6): 133–6.; Панова Е.А., Серов В.А., Шутов А.М. и др. Полипрагмазия у амбулаторных пациентов пожилого возраста. Ульяновский медико-биологический журнал. 2019; 2: 16–22. https://doi.org/10.34014/2227-1848-2019-2-16-22.; Шалыгин В.А., Ильина Е.С., Синицина И.И. и др. Лекарственно-обусловленное падение у пожилых: вклад антигипертензивных препаратов. Врач. 2019; 30 (1): 72–6. https://doi.org/10.29296/25877305-2019-01-15.; Лесонен А.С., Виноградова И.А., Лоскутова Е.Е. Исследование возможности рационального применения антигистаминных лекарственных препаратов у пожилых людей с позиции безопасности и экономической доступности. Успехи геронтологии. 2020; 33 (6): 1181–85. https://doi.org/10.34922/AE.2020.33.6.022.; Кирилочев О.О., Умерова А.Р. Контроль рациональности фармакотерапии у пациентов психиатрического стационара с синдромом старческой астении. Современные проблемы науки и образования. 2020; 6: 184. https://doi.org/10.17513/spno.30449.; Кирилочев О.О., Умерова А.Р. Анализ антихолинергической нагрузки у пожилых пациентов психиатрического профиля. Современные проблемы науки и образования. 2020; 5: 122. https://doi.org/10.17513/spno.30192.; Мусина А.З., Жамалиева Л.М., Смагулова Г.А. и др. Применение потенциально не рекомендованных препаратов в пожилом возрасте в стационарах Западного Казахстана: поперечное исследование. Медицинский журнал Западного Казахстана. 2020; 1: 41–50.; Сатыбалдиева А. Т., Шараева А. Т. Фармакоэпидемиологический анализ применения лекарственных препаратов у пожилых пациентов с гипертонической болезнью на стационарном уровне. Бюллетень науки и практики. 2020; 6 (6): 108–14. https://doi.org/10.33619/2414-2948/55/15.; Кирилочев О.О. Оценка фармакотерапии у пожилых пациентов психиатрического профиля с учетом критериев Бирса. Успехи геронтологии. 2020; 33 (2): 325–30. https://doi.org/10.34922/AE.2020.33.2.015.; Кирилочев, О.О., Тарханов В.С. Потенциально не рекомендованные лекарственные назначения и межлекарственные взаимодействия у пожилых пациентов с психическими заболеваниями. Современные проблемы науки и образования. 2021; 6: 126. https://doi.org/10.17513/spno.31224.; Батищева Г.А., Черенкова О.В., Елизарова И.О., Некрасова Н.В. Аудит лекарственных назначений у пациентов старше 65 лет в многопрофильном стационаре. Актуальные научные исследования в современном мире. 2021; 11-2: 73–81.; Мусапирова А.Б., Тулеутаева Р.Е., Махатова А.Р. и др. Оценка риска нежелательных лекарственных реакций у пожилых пациентов с сердечно-сосудистыми заболеваниями. Наука и здравоохранение. 2021; 23 (2): 118–26. https://doi.org/10.34689/SH.2021.23.2.012.; Изможерова Н.В., Попов А.А., Курындина А.А. и др. Полиморбидность и полипрагмазия у пациентов высокого и очень высокого сердечно-сосудистого риска. Рациональная фармакотерапия в кардиологии. 2022; 18 (1): 20–6. https://doi.org/10.20996/1819-6446-2022-02-09.; Изможерова Н.В., Попов А.А., Курындина А.А. и др. Анализ фармакотерапии пожилых пациентов с артериальной гипертензией. Лекарственный вестник. 2022; 23 (4): 24–34.; Ильина Е.С., Богова О.Т., Сычев Д.А. Лекарственные средства как фактор риска падений геронтологических пациентов с сердечно-сосудистыми заболеваниями с полиморбидностью. Вестник Всероссийского общества специалистов по медико-социальной экспертизе, реабилитации и реабилитационной индустрии. 2015; 4: 111–7.; Сычев Д.А., Отделенов В.А., Краснова Н.М., Ильина Е.С. Полипрагмазия: взгляд клинического фармаколога. Терапевтический архив. 2016; 88 (12): 94–102. https://doi.org/10.17116/terarkh2016881294-102.; Мусина А.З., Сейтмаганбетова Н.А., Жамалиева Л.М. и др. Индикаторы оценки рациональности лекарственной терапии. Наука и здравоохранение. 2016; 2: 29–46.; Ткачева О.Н., Переверзев А.П., Котовская Ю.В. и др. Оптимизация лекарственных назначений у пациентов пожилого и старческого возраста: можно ли победить полипрагмазию? Русский медицинский журнал. 2017; 25: 1826–8.; Павличенко С.Н., Леонова М.В., Упницкий А.А. Особенности фармакотерапии у пожилых пациентов с мультиморбидностью: критерии Бирса. Лечебное дело. 2017; 2: 18–26.; Екушева Е.В. Пожилой пациент с коморбидной патологией в практике кардиолога. Русский медицинский журнал. 2018; 2: 26–9.; Леонова, М.В., Алимова Э.Э. Клиническая фармакология в гериатрии. Клиническая геронтология. 2018; 24 (7–8): 32–9. https://doi.org/10.26347/1607-2499201807-08032-039.; Камаев Ю.О., Ященко А.В., Цибаева Е.В. Полипрагмазия: аспекты, проблемы и пути решения. Медицинский вестник МВД. 2018; 2: 32–6.; Бельдиев С.Н., Егорова И.В., Платонов Д.Ю. Рекомендации по применению пероральных антикоагулянтов у пациентов пожилого возраста: критерии Бирса и доказательная медицина. Медицина. 2019; 4: 1–11. https://doi.org/10.29234/2308-9113-2019-7-4-1-11.; Аль-Раджави А., Зырянов С.К., Ушкалова Е.А. и др. Распространeнность назначений потенциально не рекомендованных лекарственных средств в практике ведения пациентов пожилого и старческого возраста. Качественная клиническая практика. 2019; 1: 65–73. https://doi.org/10.24411/2588-0519-2019-10064.; Садовская О.Г., Гавриленко Л.Н. Полифармакотерапия у пожилых пациентов с коморбидностью: повышение комплаентности и безопасности лечения (обзор литературы). Вопросы организации и информатизации здравоохранения. 2019; 1: 120–34.; Ухтерова А.И., Ухтеров Е.А., Кудрявцева Д.А. и др. Описание критериев Бирса в согласительном документе по диагностике и лечению сердечной недостаточности у пациентов пожилого и старческого возраста. Верхневолжский медицинский журнал. 2020;. 19 (3): 16–22.; Леонова М.В. Эволюция полипрагмазии: соответствующая и проблемная полипрагмазия, выбор правильной стратегии и тактики. Медицинский совет. 2021; 14: 150–7. https://doi.org/10.21518/2079-701X-2021-14-150-157.; Ильина Е.С., Богова О.Т., Савельева М.И. и др. Результаты аудита лекарственных назначений у пациентов старческого возраста с падением в условиях стационара после обучения врачей принципам рациональной фармакотерапии. Фармакология и фармакотерапия. 2023; 4: 20–5. https://doi.org/10.46393/27132129_2023_4_20.; Владимирова Н.Н., Мясникова Е.В., Шунаев В.М. и др. Опыт мультидисциплинарного подхода к лечению пациентки с коморбидной патологией. Терапия. 2023; 8: 98–106. https://doi.org/10.18565/therapy.2023.8.98-106.; Gallagher P., Ryan C., Byrne S., et al. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Clin Pharmacol Ther. 2008; 46 (2): 72–83. https://doi.org/10.5414/cpp46072.; O’Mahony D., O’Sullivan D., Byrne S., et al. STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. Age Ageing. 2015; 44 (2): 213–8. https://doi.org/10.1093/ageing/afu145.; Hamilton H., Gallagher P., Ryan C., et al. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011; 171 (11): 1013–9. https://doi.org/10.1001/archinternmed.2011.215.; Onder G., Petrovic M., Tangiisuran B., et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. Arch Intern Med. 2010; 170 (13): 1142–8. https://doi.org/10.1001/archinternmed.2010.153.; O’Mahony D., O’Connor M., Eustace J., et al. The adverse drug reaction risk in older persons (ADRROP) prediction scale: derivation and prospective validation of an ADR risk assessment tool in older multi-morbid patients. Eur Geriatr Med. 2018; 9 (2): 191–9. https://doi.org/10.1007/s41999-018-0030-x.; Anticholinergic cognitive burden scale. Aging Brain Care. 2012 Update. URL: https://corumpharmacy.com/wp-content/uploads/2020/08/Anticholinergic-cognitive-burden-scale.pdf (дата обращения 21.05.2024).; Hill-Taylor B., Sketris I., Hayden J., et al. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013; 38 (5): 360–72. https://doi.org/10.1111/jcpt.12059.; Сычев Д.А., Бордовский С.П., Данилина К.С., Ильина Е.С. Потенциально нерекомендованные лекарственные средства для пациентов пожилого и старческого возраста: STOPP/START критерии. Клиническая фармакология и терапия. 2016; 25 (2): 76–81.; https://www.pharmacoeconomics.ru/jour/article/view/1047
-
9Academic Journal
Authors: Beregovykh V.V., Panteleev V.I., Shimanovsky N.L.
Contributors: 0
Source: Annals of the Russian academy of medical sciences; Vol 79, No 4 (2024); 346-352 ; Вестник Российской академии медицинских наук; Vol 79, No 4 (2024); 346-352 ; 2414-3545 ; 0869-6047 ; 10.15690/vramn.794
Subject Terms: polypharmacy, adverse drug reactions, artificial intelligence, clinical decision support system, полифармакотерапия, нежелательные лекарственные реакции, искусственный интеллект, система поддержки принятия врачебных решений
File Description: application/pdf
Relation: https://vestnikramn.spr-journal.ru/jour/article/view/17965/2016; https://vestnikramn.spr-journal.ru/jour/article/view/17965/2026; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/17965/145580; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/17965/145581
-
10Academic Journal
Source: Наука и здравоохранение. :118-126
Subject Terms: Beers criteria, pharmacotherapy, adverse drug reactions, Бирстің критерилері, gerontology, критерии Бирса, геронтология, фармакотерапия, нежелательные лекарственные реакции, polypharmacy, жағымсыз дәрілік реакциялар, полипрагмазия, 3. Good health
-
11Academic Journal
Authors: S. A. Mishinova, A. A. Zhuravkov, V. K. Zhuravko
Source: Качественная клиническая практика, Vol 0, Iss 4S, Pp 120-129 (2020)
Subject Terms: клиническая фармакология, расширенный доступ, реальная клиническая практика, 3. Good health, RS1-441, жизнеугрожающие заболевания, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, covid-19, Medical technology, off-label назначение, нежелательные лекарственные реакции, R855-855.5
Access URL: https://www.clinvest.ru/jour/article/download/542/550
https://doaj.org/article/2e28d4f3fcf94b8ebdc51bd2fb4d1ca2
https://www.clinvest.ru/jour/article/view/542
https://www.clinvest.ru/jour/article/download/542/550
https://cyberleninka.ru/article/n/naznachenie-ofitsialno-ne-razreshyonnyh-k-primeneniyu-lekarstvennyh-sredstv-i-ispolzovanie-lekarstvennyh-sredstv-s-narusheniem
https://cyberleninka.ru/article/n/naznachenie-ofitsialno-ne-razreshyonnyh-k-primeneniyu-lekarstvennyh-sredstv-i-ispolzovanie-lekarstvennyh-sredstv-s-narusheniem/pdf -
12Academic Journal
Authors: R. R. Shakirov, I. S. Basin, T. V. Krashikhina, A. I. Tekeeva, E. S. Chernysheva, K. V. Lyadov, Р. Р. Шакиров, И. С. Базин, Т. В. Крашихина, А. И. Текеева, Е. С. Чернышева, К. В. Лядов
Source: Malignant tumours; Том 13, № 2 (2023); 107-112 ; Злокачественные опухоли; Том 13, № 2 (2023); 107-112 ; 2587-6813 ; 2224-5057
Subject Terms: ингибиторы контрольных точек, нежелательные лекарственные реакции, саркоидоз
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1103/791; Martins F., Sofiya L., Sykiotis G. P., Lamine F., Maillard M., Fraga M., Shabafrouz K. et al. Adverse effects of immune-checkpoint inhibitors : epidemiology, management and surveillance // Nat. Rev. Clin. Oncol, 2019, том 16 № 9, стр. 563-580.; Wang D.Y., Salem J .- E., Cohen J.V., Chandra S., Menzer C., Ye F. et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors : A Systematic Review and Meta-analysis // JAMA Oncol, 2018, том 4, № 12. стр. 1721-1728. Chopra A., Nautiyal A., Kalkanis A., Judson M. A. Drug-Induced Sarcoidosis-Like Reactions // Chest, 2018, том Sep 154 (3), стр. 664-677.; El Jammal T., Pavic M., Gerfaud-Valentin M., Jamilloux Y., Seve P. Sarcoidosis and Cancer : A Complex Relationship// Front. Med., 2020, том 7, статья 594118.; Jespersen H., Bjursten S., Ny L., Levin M. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases// Lancet Oncol., 2018, том 19 (6) : e327.; Purohit B. S., Ailianou A., Dulguerov N., Becker C.D., Ratib O., Becker M. FDG-PET / CT pitfalls in oncological head and neck imaging// Insights Imaging, 2014, том 5, стр. 585-602.; Takamochi K., Yoshida J., Murakami K., Niho S., Ishii G., Nishimura M. et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients // Lung Cancer, 2004, том 47 (2), стр. 235-242. Kruger S., Buck A.K., Mottaghy F.M., Pauls S., Schelzig H., Hombach V. et al. Use of integrated FDG-PET / CT in sarcoidosis// Clin. Imaging, 2008, том 32 (4), стр. 269-273.; Ammar A., Zahia E., Bali, Daniel S. et al. Sarcoidosis-Like Granulomatous Lymphadenopathy Mistaken for Neoplastic Disease on Positron Emission Tomography// J. Investig. Med. High Impact Case Rep., 2019, том 7, стр. 1-3.; https://www.malignanttumors.org/jour/article/view/1103
-
13Academic Journal
Authors: O. Ostroumova D, M. Chernyaeva S., A. Kochetkov I., A. Vorobieva E., D. Bakhteeva I., S. Korchagina P., O. Bondarets V., N. Boyko D., D. Sychev A., О. Остроумова Д., М. Черняева С., А. Кочетков И., А. Воробьева Е., Д. Бахтеева И., С. Корчагина П., О. Бондарец В., Н. Бойко Д., Д. Сычев А.
Source: Rational Pharmacotherapy in Cardiology; Vol 17, No 6 (2021); e1-e18 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 6 (2021); e1-e18 ; 2225-3653 ; 1819-6446
Subject Terms: drug-induced atrial fibrillation, adverse drug reactions, anticancer drugs, bisphosphonates, glucocorticoids, nonsteroidal anti-inflammatory drugs, immunosuppressants, local anesthetics, anabolic steroids, nicotine, лекарственно-индуцированная фибрилляция предсердий, нежелательные лекарственные реакции, противоопухолевые лекарственные средства, бисфосфонаты, глюкокортикоиды, нестероидные противовоспалительные средства, иммунодепрессанты, местные анестетики, анаболические стероиды, никотин
File Description: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2636/2269; 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.; 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78. DOI:10.1093/europace/euw295.; Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-52. DOI:10.1161/01.cir.98.10.946.; Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. The Am J Med. 2002;113(5):359-64. DOI:10.1016/s0002-9343(02)01236-6.; Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case control study. Eur Heart J. 2013;34(14):1061-7. DOI:10.1093/eurheartj/ehs469.; Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103-8. DOI:10.1161/STROKEAHA.113.00232.; Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486. DOI:10.1161/JAHA.114.001486.; Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. DOI:10.1161/CIRCULATIONAHA.113.00511.; Wolf PA, Abbott R, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22(8):983-8. DOI:10.1161/01.str.22.8.983.; Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36(7):2242-6. DOI:10.1016/s0735-1097(00)00982-7.; Halligan SC, Gersh BJ, Brown RD Jr, et al. The natural history of lone atrial flutter. Ann Intern Medю 2004;140(4):265-8. DOI:10.7326/0003-4819-140-4-200402170-00008.; Фибрилляция и трепетание предсердий. Клинические рекомендации 2020 г.» [цитировано 30.06.2021. Доступно на: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf].; Dobrev D, Friedrich A, Voigt N, et al. The G protein-gated potassium current I (K, A Ch) is constitutively active in patients with chronic atrial fibrillation. Circulation. 2005;112(24):3697-706. DOI:10.1161/CIRCULATIONAHA.105.575332.; Van Wagoner DR, Pond AL, Lamorgese M, et al. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res. 1999;85(5):428-36. DOI:10.1161/01.res.85.5.428.; van der Hooft CS, Heeringa J, van HG, et al. Drug-induced atrial fibrillation. J Am Coll Cardiol. 2004;44(11):2117-24. DOI:10.1016/j.jacc.2004.08.053; Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018; Остроумова О.Д., Черняева М.С., Комарова А.Г., и др. Лекарственно-индуцированная фибрилляция предсердий, ассоциированная с приемом сердечно-сосудистых лекарственных средств. Сибирское Медицинское Обозрение. 2020;(6):5-13. DOI:10.20333/2500136-2020-6-5-13.; Tamargo J, Caballero R, Delpón E. Drug-induced atrial fibrillation: does it matter? Discovery Medicine. 2012;14(78):295-9.; Остроумова О.Д., Черняева М.С., Масленникова О.М., и др. Лекарственно-индуцированная фибрилляция/трепетание предсердий, ассоциированная с приемом лекарственных средств, влияющих на центральную нервную систему. Фарматека. 2021;(3):10-7. DOI:10.18565/pharmateca.; Остроумова О.Д., Черняева М.С., Кочетков А.И., и др. Лекарственно-индуцированная фибрилляция предсердий, ассоциированная с применением противоопухолевых лекарственных средств. Безопасность и Риск Фармакотерапии. 2020;8(4):178-90. DOI:10.30895/2312-7821-2020-8-4-178-190.; Остроумова О.Д., Черняева М.С., Бахтеева Д.И., и др. Отдельные группы лекарственных средств, прием которых ассоциирован с развитием лекарственно-индуцированной фибрилляции предсердий. Медицинский Алфавит. 2021;1(11):20-8. DOI:10.33667/2078-5631-2021-11-20-28.; Strickberger SA, Man KC, Daoud EG. Adenosine-induced Atrial Arrhythmia: A Prospective Analysis. Ann Intern Med. 1997;127(6):417-22. DOI:10.7326/0003-4819-127-6-199709150-00001; Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation. 1999;99(8):1034-40. DOI:10.1161/01.cir.99.8.1034.; Camaiti A, Pieralli F, Olivotto I, et al. Prospective evaluation of adenosine-induced proarrhythmia in the emergency room. Eur J Emerg Med. 2001;8(2):99-105 DOI:10.1097/00063110-200106000-00005.; Belhassen B, Pelleg A, Shoshani D. Atrial Fibrillation Induced by Adenosine Triphosphate. Am J Cardiol. 1984;53(9):1405-6. DOI:10.1016/0002-9149(84)90104-8.; Garratt CJ, Antoniou A, Griffith MJ, Ward DE. Use of Intravenous Adenosine in Sinus Rhythm as a Diagnostic Test for Latent Preexcitation. Am J Cardiol. 1990;65(13):868-73. DOI:10.1016/0002-9149(90)91428-9.; Meurer MK. A 21-year-old Woman With Rapid Atrial Fibrillation After Adenosine Administration. J Emerg Nurs. 1991;17(3):135-6.; Cowell RP, Paul VE, Ilsley CD. Haemodynamic Deterioration After Treatment With Adenosine. Br Heart J. 1994;71(6):569-71. DOI:10.1136/hrt.71.6.569.; Crosson JE, Etheridge SP, Milstein S. Therapeutic and Diagnostic Utility of Adenosine During Tachycardia Evaluation in Children. Am J Cardiol. 1994;74(2):155-60. DOI:10.1016/0002-9149(94)90089-2.; Tebbenjohanns J, Pfeiffer D, Schumacher B, et al. Intravenous Adenosine During Atrioventricular Reentrant Tachycardia: Induction of Atrial Fibrillation With Rapid Conduction Over an Accessory Pathway. Pacing Clin Electrophysiol. 1995;18(4):743-6. DOI:10.1111/j.1540-8159.1995.tb04673.x.; Silverman AJ, Machado C, Baga JJ, et al. Adenosine-induced Atrial Fibrillation. Am J Emerg Med. 1996;14(3):300-1. DOI:10.1016/S0735-6757(96)90182-5.; Kaplan IV, Kaplan AV, Fisher JD. Adenosine Induced Atrial Fibrillation Precipitating Polymorphic Ventricular Tachycardia. Pacing Clin Electrophysiol. 2000;23(1):140-1. DOI:10.1111/j.1540-8159.2000.tb00662.x; Israel C, Klingenheben T, Grönefeld G. Adenosine-induced Atrial Fibrillation. J Cardiovasc Electrophysiol. 2000;11(7):825. DOI:10.1111/j.1540-8167.2000.tb00057.x.; Jonathan RK, Ronn ET, Maully JSh, et al. Induction of Atrial Fibrillation After the Routine Use of Adenosine. Pediatr Emerg Care. 2006;22(2):113-5. DOI:10.1097/01.pec.0000199558.88733.49.; Matthew C, Jaffar R, Assad M. Atrial Fibrillation During Adenosine Pharmacologic Stress Testing. J Nucl Cardiol. 2006;13(4):576-81. DOI:10.1016/j.nuclcard.2006.05.006.; Stuber T, Lim PB, O'Neill MD, Peters NS. Ultra Rapid Local Activity in Adenosine-Induced Atrial Fibrillation. J Cardiovasc Electrophysiol. 2008;19(5):566-7. DOI:10.1111/j.1540-8167.2007.01044.x.; Kanei Y, Hanon S, Van-Tosh A, Schweitzer P. Adenosine-induced Atrial Fibrillation During Pharmacologic Stress Testing: Report of Eight Cases and Review of the Literature. Int J Cardiol. 2008;129(1):e15-7. DOI:10.1016/j.ijcard.2007.05.090.; Turley AJ, Murray S, Thambyrajah J. Pre-excited Atrial Fibrillation Triggered by Intravenous Adenosine: A Commonly Used Drug With Potentially Life-Threatening Adverse Effects. Emerg Med J. 2008;25(1):46-8. DOI:10.1136/emj.2007.051227.; Park E, Price A, Vidovich MI. Adenosine-induced Atrial Fibrillation During Fractional Flow Reserve Measurement. Cardiol J. 2012;19(6):650-1. DOI:10.5603/cj.2012.0121.; Walter JHJr, Patricia ETh, Christopher SS. Induction of Atrial Fibrillation With Adenosine During a Transesophageal Electrophysiology Study to Risk Stratify a Patient With Asymptomatic Ventricular Preexcitation. Congenit Heart Dis. 2013;8(4):E99-E101. DOI:10.1111/j.1747-0803.2012.00682.x.; Salaria V, Mehta NJ, Abdul-Aziz S, et al. Role of postoperative use of adrenergic drugs in occurrence of atrial fibrillation after cardiac surgery. Clin Cardiol. 2005;28(3):131-5. DOI:10.1002/clc.4960280306.; Kane GC, Hepinstall MJ, Kidd GM, et al. Safety of stress echocardiography supervised by registered nurses: results of a 2-year audit of 15,404 patients. J Am Soc Echocardiogr. 2008;21(4):337-41. DOI:10.1016/j.echo.2007.08.028.; Carasso S, Sandach A, Kuperstein R, et al. Atrial fibrillation in dobutamine stress echocardiography. Int J Cardiol. 2006;111(1):53-8. DOI:10.1016/j.ijcard.2005.07.001.; Mertes H, Sawada SG, Ryan T, et al. Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients. Circulation. 1993;88:15-9. DOI:10.1161/01.cir.88.1.15.; Secknus MA, Marwick TH. Evolution of dobutamine echocardiography protocols and indications: safety and side effects in 3,011 studies over 5 years. J Am Coll Cardiol. 1997;29(6):1234-40. DOI:10.1016/s0735-1097(97)00039-9.; Feneck RO, Sherry KM, Withington PS, et al. Comparison of the Hemodynamic Effects of Milrinone With Dobutamine in Patients After Cardiac Surgery. J Cardiothorac Vasc Anesth. 2001;15(3):30615. DOI:10.1053/jcan.2001.23274.; Baig MW, Sheard K, Thorley PJ, et al. The Use of Dobutamine Stress Thallium Scintigraphy in the Diagnosis of Syndrome X. Postgrad Med J. 1992;68 Suppl 2:S20-4.; Poldermans D, Fioretti PM, Boersma E. et al. Safety of Dobutamine-Atropine Stress Echocardiography in Patients With Suspected or Proven Coronary Artery Disease. Am J Cardiol. 1994;73(7):456-9. DOI:10.1016/0002-9149(94)90675-0.; Wirtz CE. Sustained Atrial Fibrillation After Dobutamine Stress Echocardiography in an Older Patient With Left Atrial Enlargement. West J Med. 1995;162(3):268-9.; Cornel JH, Balk AH, Boersma E, et al. Safety and feasibility of dobutamine-atropine stress echocardiography in patients with ischemic left ventricular dysfunction. J Am Soc Echocardiogr. 1996;9(1):27-32. DOI:10.1016/s0894-7317(96)90101-7.; Yeo TC, Ng WL, Ling LH, et al. Dobutamine stress echocardiography in the elderly Asian patients. Ann Acad Med Singap. 1997;26(2):165-7.; Pezzano A, Gentile F, Mantero A, et al. [RITED (RegistroItaliano Test Eco-Dobutamina): side effects and complications of echo-dobutamine stress test in 3041 examinations]. Giornaleitaliano di Cardiologia. 1998;28(2):102-11 (In Italian).; Elhendy A, van Domburg RT, Bax JJ, et al. Safety, hemodynamic profile, and feasibility of dobutamine stress technetium myocardial perfusion single-photon emission CT imaging for evaluation of coronary artery disease in the elderly. Chest. 2000;117(3):649-56. DOI:10.1378/chest.117.3.649.; Coisne D, Donal E, Torremocha F, et al. Dobutamine stress echocardiography response of asymptomatic patients with diabetes. Echocardiography. 2001;18(5):373-9. DOI:10.1046/j.1540-8175.2001.00373.x.; Cortigiani L, Zanetti L, Bigi R, et al. Safety and feasibility of dobutamine and dipyridamole stress echocardiography in hypertensive patients. J Hypertens. 2002;20(7):1423-9. DOI:10.1097/00004872-200207000-00030.; Wahl A, Paetsch I, Gollesch A, et al. Safety and feasibility of high-dose dobutamine-atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases. Eur Heart J. 2004;25(14):1230-6. DOI:10.1016/j.ehj.2003.11.018.; Onorati F, Renzulli A, De Feo M, et al. Perioperative enoximone infusion improves cardiac enzyme release after CABG. J Cardiothorac Vasc Anesth. 2004;18(4):409-14 DOI:10.1053/j.jvca.2004.05.016.; Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883-91. DOI:10.1001/jama.297.17.1883.; Sheldon SH, Askew JW 3rd, Klarich KW, et al. Occurrence of atrial fibrillation during dobutamine stress echocardiography: incidence, risk factors, and outcomes. J Am Soc Echocardiogr. 2011;24(1):86-90. DOI:10.1016/j.echo.2010.10.008.; Argalious M, Motta P, Khandwala F, et al. "Renal dose" dopamine is associated with the risk of newonset atrial fibrillation after cardiac surgery. Crit Care Med. 2005;33(6):1327-32. DOI:10.1097/01.ccm.0000166876.41694.ca.; Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(12):1541–7. DOI:10.1001/jama.287.12.1541.; Wright EM, Sherry KM. Clinical and haemodynamic effects of milrinone in the treatment of low cardiac output after cardiac surgery. Br J Anaesth. 1991;67(5):585-90. DOI:10.1093/bja/67.5.585.; Feneck RO. Intravenous milrinone following cardiac surgery: II. Influence of baseline hemodynamics and patient factors on therapeutic response. The European Milrinone Multicentre Trial Group. J Cardiothorac Vasc Anesth. 1992;6(5):563-7. DOI:10.1016/1053-0770(92)90098-r.; Fleming GA, Murray KT, Yu C, et al. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation. 2008;118(16):1619-25. DOI:10.1161/CIRCULATIONAHA.108.790162.; Smith AH, Owen J, Borgman KY, et al. Relation of milrinone after surgery for congenital heart disease to significant postoperative tachyarrhythmias. Am J Cardiol. 2011;108(11):1620-4. DOI:10.1016/j.amjcard.2011.07.023.; Acharya D, Sanam K, Revilla-Martinez M, et al. Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy. Am J Cardiol. 2016;117(6):952-6. DOI:10.1016/j.amj-card.2015.12.030.; Tai CT, Chiang CE, Lee SH, et al. Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. J Cardiovasc Electrophysiol. 1999;10(9):1180-7. DOI:10.1111/j.1540-8167.1999.tb00293.x.; Donald HSc, Melissa SD. Paroxysmal Atrial Fibrillation Precipitated by Amiodarone-Induced Thyrotoxicosis Five Months After Cessation of Therapy. J Emerg Med. 2006;31(1):61-4. DOI:10.1016/j.jemermed.2005.08.011.; Ibrahim HK, Talat Y, Bulent MK. Atrial Fibrillation Due to Late Amiodarone-Induced Thyrotoxicosis. Clin Drug Investig. 2008;28(8):527-31. DOI:10.2165/00044011-200828080-00008.; Остроумова О.Д., Качан В.О., Кочетков А.И., Краснов Г.С. Лекарственно-индуцированный гипотиреоз. Фарматека. 2020;27(3):107-17. DOI:10.18565/pharmateca.2020.3.107-117.; Гайсёнок О.В. Нарушения сердечного ритма в реальной врачебной практике: амиодарон-индуцированный тиреотоксикоз 2-го типа как причина рецидивирующей фибрилляции предсердий. Рациональная Фармакотерапия в Кардиологии. 2010;6(4):518-21. DOI:10.20996/1819-6446-2010-6-4-518-521.; Reithmann C, Hoffmann E, Spitzlberger G, et al. Catheter Ablation of Atrial Flutter Due to Amiodarone Therapy for Paroxysmal Atrial Fibrillation. Eur Heart J. 2000;21(7):565-72. DOI:10.1053/euhj.1999.1865.; Kaakeh Y, Overholser BR, Lopshire JC, Tisdale E. Drug-Induced Atrial Fibrillation. Drugs. 2012;72(12):1617-30. DOI:10.2165/11633140-000000000-00000.; Tamargo J, Delpon E, Caballero R. The safety of digoxin as a pharmacological treatment of atrial fibrillation. Expert Opin Drug Saf. 2006;5(3):453-67. DOI:10.1517/14740338.5.3.453.; Sticherling C, Oral H, Horrocks J, et al. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation. 2000;102(20):2503-8. DOI:10.1161/01.cir.102.20.2503.; Digitalis Investigation Group. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New Engl J Med. 1997;336(8):525-33. DOI:10.1056/NEJM199702203360801.; Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871-8. DOI:10.1001/jama.289.7.871.; Мареев В.Ю., Фомин И.В., Агеев Ф.Т, и др. Клинические рекомендации ОССН-РКО-РНМОТ. сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. DOI:10.18087/cardio.2475.; Nabar A, Rodriguez LM, Timmermans C, et al. Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. Heart. 2001;85(4):424-9. DOI:10.1136/heart.85.4.424.; Murdock CJ. Atrial Flutter in Patients Treated for Atrial Fibrillation With Propafenone. Am J Cardiol. 1990;66(7):755-7. DOI:10.1016/0002-9149(90)91144-u.; Feld GK, Chen PS, Nicod P, et al. Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs. Am J Cardiol. 1990;66(3):378-83. DOI:10.1016/0002-9149(90)90856-v.; Aliot E, De Roy L, Capucci A, et al. Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. Ann Cardiol Angéiol (Paris). 2003;52(1):34-40. DOI:10.1016/s0003-3928(02)00183-x.; Shenasa M, Kus T, Fromer M, et al. Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. Am J Cardiol. 1988;62(7):403-7. DOI:10.1016/0002-9149(88)90967-8.; Isomoto S, Shimizu A, Knoe A, et al. Effects of intravenous verapamil on atrial vulnerability. Jpn Circ J. 1994;58(1):1-8. DOI:10.1253/jcj.58.1.; Falk RH. Etiology and complications of atrial fibrillation: insights from pathology studies. Am J Cardiol. 1998;82(8A):10N-17N. DOI:10.1016/s0002-9149(98)00735-8.; Falk RH, Knowlton AA, Manaker S. Verapamil-induced Atrial Fibrillation. N Engl J Med. 1988;318(10):640-1. DOI:10.1056/NEJM198803103181014.; Garratt C, Linker N, Griffith M, et al. Comparison of Adenosine and Verapamil for Termination of Paroxysmal Junctional Tachycardia. Am J Cardiol. 1989;64(19):1310-6. DOI:10.1016/0002-9149(89)90573-0.; Parasuraman R, Gandhi MM, Liversedge NH. Nifedipine tocolysis associated atrial fibrillation responds to DC cardioversion. BJOG. 2006;113(7):844-5. DOI:10.1111/j.1471-0528.2006.00964.x.; Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85. DOI:10.1016/S0140-6736(10)61198-1.; Fox K, Ford I, Gabriel Ph, et al. Jean-Claude Tardif, Michal Tendera, Roberto Ferrari, SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091-9. DOI:10.1056/NEJMoa1406430.; Fox K, Ford I, Gabriel Ph, et al. Bradycardia and Atrial Fibrillation in Patients With Stable Coronary Artery Disease Treated With Ivabradine: An Analysis From the SIGNIFY Study. Eur Heart J. 2015;36(46):3291-6. DOI:10.1093/eurheartj/ehv451.; Cammarano C, Silva M, Comee M, et al. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction. Clini Ther. 2016;38(2):387-95. DOI:10.1016/j.clinthera.2015.12.018.; Mengesha HG, Weldearegawi B, Petrucka P, et al. Effect of Ivabradine on Cardiovascular Outcomes in Patients With Stable Angina: Meta-Analysis of Randomized Clinical Trials. BMC Cardiovasc Disord. 2017;17(1):105. DOI:10.1186/s12872-017-0540-3.; Martin RI, Pogoryelova O. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100(19):1506-10. DOI:10.1136/heartjnl-2014-305482.; Tanboğa İH, Topçu S, Aksakal E, et al. The Risk of Atrial Fibrillation With Ivabradine Treatment: A Metaanalysis With Trial Sequential Analysis of More Than 40000 Patients. Clin Cardiol. 2016;39(10):615-20. DOI:10.1002/clc.22578.; Emara MK, Saadet AM. Transient atrial fibrillation in hypertensive patients with thiazide induced hypokalaemia. Postgrad Med J. 1986;62(734):1125-7. DOI:10.1136/pgmj.62.734.1125.; Zhang N, Chen K, Zhao J, et al. Another Side Effect of Ticagrelor: Atrial Fibrillation. Int J Cardiol. 2016;212:242-4. DOI:10.1016/j.ijcard.2016.03.091.; McCune KH, O’Brien CJ. Atrial fibrillation induced by ibuprofen overdose. Postgrad Med J. 1993;69(810):325-6. DOI:10.1136/pgmj.69.810.325-a.; Vasheghani-Farahani A, Sahraian MA, Darabi L, et al. Incidence of Various Cardiac Arrhythmias and Conduction Disturbances Due to High Dose Intravenous Methylprednisolone in Patients With Multiple Sclerosis. J Neurol Sci. 2011;309(1-2):75-8. DOI:10.1016/j.jns.2011.07.018.; McLuckie AE, Savage RW. Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest. 1993;104(2):622-3. DOI:10.1378/chest.104.2.622.; Moretti R, Torre P, Antonello RM, et al Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment. Eur J Neurol. 2000;7(1):130. DOI:10.1046/j.1468-1331.2000.00026.x.; Ueda N, Yoshikawa T, Chihara M, et al. Atrial fibrillation following methylprednisolone pulse therapy. Pediatr Nephrol. 1988;2(1):29-31. DOI:10.1007/BF00870376.; Yamamura K, Ohga S, Nishiyama K, et al. Recurrent atrial fibrillation after high-dose methylprednisolone therapy in a girl with lupus-associated hemophagocytic syndrome. Lupus 2011;20(8):871-5. DOI:10.1177/0961203310392429.; Aslam AK, Vasavada BC, Sacchi TJ, Khan IA. Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone. Am J Ther. 2001;8(4):303–5. DOI:10.1097/00045391-200107000-00013.; Dogukan A, Ilkay E, Poyrazoglu OK, et al. Atrial fibrillation due to oral methylprednisolone in a patient with membranoproliferative glomerulonephritis. Acta Medica (Hradec Kralove). 2008;51(1):63-4. DOI:10.14712/18059694.2017.34.; Iqbal FM, Beeharilal PS, Sadat K, et al. Steroid induced atrial fibrillation. Compr Ther. 2008;34(2):111–4.; van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016-20. DOI:10.1001/archinte.166.9.1016.; De CR, Ruigomez A, Rodriguez LA. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med. 2010;170(16):1450-5. DOI:10.1001/archinternmed.2010.305.; Oteri A, Bussolini A, Sacchi M, et al. A case of atrial fibrillation induced by inhaled fluticasone propionate. Pediatrics. 2010;126(5):e1237-41. DOI:10.1542/peds.2010-0419.; De Caterina R, Ruigomez A, Rodriguez LA. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med. 2010;170(16):1450-5. DOI:10.1001/archinternmed.2010.305.; Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011;343:d3450. DOI:10.1136/bmj.d3450.; Merli GJ, Weitz H, Martin JH, et al. Cardiac dysrhythmias associated with ophthalmic atropine. Arch Intern Med. 1986;146(1):45-7.; Sueda S, Ochi N, Kawada H, et al. Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am J Cardiol. 1999;83(8):1186-90. DOI:10.1016/s0002-9149(99)00057-0.; Sueda S, Fukuda H, Watanabe K, et al. Clinical characteristics and possible mechanism of paroxysmal atrial fibrillation induced by intracoronary injection of acetylcholine. Am J Cardiol. 2001;88(5):570-3. DOI:10.1016/s0002-9149(01)01744-1.; Low RA Jr, Fuller MA, Popli A. Clozapine induced atrial fibrillation. J Clin Psychopharmacol. 1998;18(2):170. DOI:10.1097/00004714-199804000-00010.; Shaibani A, Fares S, Selam, et al. Lacosamide in painful diabetic neuropathy: an 18-week double blind placebo controlled trial. J Pain. 2009;10(8):818-28. DOI:10.1016/j.jpain.2009.01.322.; De Giorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav. 2010;18(3):322-4. DOI:10.1016/j.yebeh.2010.04.043.; Lee CW, Muo CH, Liang JA, et al. Atrial Fibrillation is Associated With Morphine Treatment in Female Breast Cancer Patients: A Retrospective Population-Based Time-Dependent Cohort Study. Medicine (Baltimore). 2016;95(11):e3102. DOI:10.1097/MD.0000000000003102.; Peacock WF, Hollander JE, Diercks DB, et al. Morphine and Outcomes in Acute Decompensated Heart Failure: An ADHERE Analysis. Emerg Med J. 2008;25(4):205-9. DOI:10.1136/emj.2007.050419.; Sabzi F, Zokaei AH, Moloudi AR. Predictors of atrial fibrillation following coronary artery bypass grafting. Clin Med Insights Cardiol. 2011;5:67-75. DOI:10.4137/CMC.S7170.; Waters BM, Joshi KG, Flynn J. Olanzapine-Associated New-Onset Atrial Fibrillation. J Clin Psychopharmacol. 2008;28(3):354-5. DOI:10.1097/JCP.0b013e318173082c.; Davis LE, Becher MW, Tlomak W, et al. Persistent choreoathetosis in a fatal olanzapine overdose: drug kinetics, neuroimaging, and neuropathology. Am J Psychiatry. 2005;162(1):28-33. DOI:10.1176/appi.ajp.162.1.28.; Yaylaci S, Tamer A, Kocayigit I, Gunduz H. Atrıal fıbrıllatıon due to olanzapine overdose. Clin Toxicol (Phila). 2011;49(5):440. DOI:10.3109/15563650.2011.588605.; Kasinath NS, Malak O, Tetzlaff J. Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. Can J Anaesth. 2003;50(3):229-31. DOI:10.1007/BF03017789.; Havrilla PL, Kane-Gill SL, Verrico MM, et al. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother. 2009;43(3):532-6. DOI:10.1345/aph.1L544.; Schneider RA, Lizer MH. Apparent seizure and atrial fibrillation associated with paliperidone. Am J Health Syst Pharm. 2008;65(22):2122-5. DOI:10.2146/ajhp070615.; Morgan DR, Trimble M, McVeigh GE. Atrial fibrillation associated with sumatriptan. BMJ. 2000;321(7256):275. DOI:10.1136/bmj.321.7256.275.; Devadathan S, Gunning M. Atrial fibrillation following oral sumatriptan administration. Int J Cardiol. 2006;107(1):112-3. DOI:10.1016/j.ijcard.2004.11.039.; White WB, Wong SH. Rapid atrial fibrillation associated with trazodone hydrochloride. Arch Gen Psychiatry. 1985;42(4):424. DOI:10.1001/archpsyc.1985.01790270114017.; Qureshi WT, O’Neal WT, Khodneva Y, et al. Association between opioid use and atrial fibrillation: the reasons for geographic and racial differences in stroke (REGARDS) study. JAMA Intern Med. 2015;175(6):1058-60. DOI:10.1001/jamainternmed.2015.1045.; Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry. 1991;52(4):174-6.; Roberge RJ, Martin G. Mixed fluoxetine/loxapine overdose and atrial flutter. Ann Emerg Med. 1994;23(3):586-90. DOI:10.1016/s0196-0644(94)70083-4.; Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20(1):205-13. DOI:10.1200/JCO.2002.20.1.205.; Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood. 2004;104(3):655-8. DOI:10.1182/blood-2003-07-2345.; Gridelli C, Cigolari S, Gallo C, et al. MILES Investigators. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001;31(2-3):277-84. DOI:10.1016/s0169-5002(00)00194-x.; Tavil Y, Arslan U, Okyay K, et al. Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man. Onkologie. 2007;30(5):253-5. DOI:10.1159/000100930.; Santini D, Tonini G, Abbate A, et al. Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. Ann Oncol. 2000;11(4):479-81. DOI:10.1023/a:1008380208045.; Ciotti R, Belotti G, Facchi E, et al. Sudden cardiopulmonary toxicity following a single infusion of gemcitabine. Ann Oncol. 1999;10(8):997. DOI:10.1023/a:1008305716918.; Ferrari D, Carbone C, Codeca C, et al. Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity. Anticancer Drugs. 2006;17(3):359-61. DOI:10.1097/00001813-200603000-00016.; Numico G, Castiglione F, Granetto C, et al. Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer. 2002;35(1):59-64. DOI:10.1016/s0169-5002(01)00269-0.; Kilickap S, Barista I, Akgul E, et al. Early and late arrhythmogenic effects of doxorubicin. South Med J. 2007;100(3):262-5. DOI:10.1097/01.smj.0000257382.89910.fe.; Dindogru A, Barcos M, Henderson ES, Wallace HJJr. Electrocardiographic changes following adriamycin treatment. Med Pediatr Oncol. 1978;5(1):65-71. DOI:10.1002/mpo.2950050110; Oster MW, Rakowski TJ. Myocardial injury immediately following adriamycin administration. Med Pediatr Oncol. 1981;9(5):463-5. DOI:10.1002/mpo.2950090508.; Montella L, Caraglia M, Addeo R, et al. Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert’s disease). Ann Hematol. 2005;84(3):192-3. DOI:10.1007/s00277-004-0867-6.; Palma M, Mancuso A, Grifalchi F. Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report. Tumori 2002;88(6):527-9.; Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138-40. DOI:10.1182/blood-2016-05-712828.; Yun S, Vincelette ND, Acharya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2017;17(1):31-37.e13. DOI:10.1016/j.clml.2016. 09.010.; Caldeira D, Alves D, Costa J, et al. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One 2019;14(2):e0211228. DOI:10.1371/journal.pone.0211228.; Емелина Е.И., Гендлин Г.Е., Никитин И.Г., и др. Нарушения ритма и проводимости у пациентов, получающих лечение ибрутинибом. Клиническая Онкогематология. 2019;12(2):220-30. DOI:10.21320/2500-2139-2019-12-2-220-230.; Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58(7):1630–9. DOI:10.1080/10428194.2016.1257795.; Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7(1):7-20. DOI:10.1200/JCO.1989.7.1.7.; Dutcher JP, Fisher RI, Weiss G, et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am. 1997;3(3):157-62.; Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989;7(4):486-98. DOI:10.1200/JCO.1989.7.4.486.; Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118(1):31-6. DOI:10.7326/0003-4819-118-1-199301010-00006.; Illiano A, Barletta E, De Marino V, et al. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study. Anticancer Res. 2000;20(5C):3999–4003.; Pérez PE, Mesa MG, García SPJ, González RAP. Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. Adv Ther. 2011;28 Suppl 1:11-6. DOI:10.1007/s12325-010-0102-x.; Olivieri A, Corvatta L, Montanari M, et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant. 1998;21(10):1049-53. DOI:10.1038/sj.bmt.1701217.; Moreau P, Milpied N, Mahé B, et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 1999;23(10):1003-6. DOI:10.1038/sj.bmt.1701763.; Phillips GL, Meisenberg B, Reece DE, et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant. 2004;10(7):473-83. DOI:10.1016/j.bbmt.2004.03.001.; Feliz V, Saiyad S, Ramarao SM, et al. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34(6):356-9. DOI:10.1002/clc.20904.; Sirohi B, Powles R, Treleaven J, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000;25(5):533-9. DOI:10.1038/sj.bmt.1702188.; Mileshkin LR, Seymour JF, Wolf MM, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stern cell transplantation for patients aged 60 years and older. Leuk Lymphoma. 2005;46(11):1575-9. DOI:10.1080/1042819050023588.; Zingler VC, Nabauer M, Jahn K. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol. 2005;54(1):28-33. DOI:10.1159/000087242.; Kamineni P, Prakasa K, Hasan SP, et al. Cardiotoxicities of paclitaxel in African Americans. J Natl Med Assoc. 2003;95(10):977-81.; Lombardi D, Crivellari D, Scuderi C, et al. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori. 2004;90(3):285-8.; Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993;(15):117-30.; Guglin M, Aljayeh M, Saiyad S, et al. Introducing a new entity: chemotherapy-induced arrhythmia. Europace. 2009;11(12):1579-86. DOI:10.1093/europace/eup300.; Moscetti L, Ramponi S, Maccaglia C, et al. Atrial fibrillation in a patient with non-small-cell carcinoma of the lung in the course of paclitaxel therapy. Clin Ter. 1998;149(5):377-9.; Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18(2):317-24. DOI:10.1200/JCO.2000.18.2.317.; Mego M, Reckova M, Obertova J, et al. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol. 2007;18(11):1906-7. DOI:10.1093/annonc/mdm489.; Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99(9):727-37. DOI:10.1093/jnci/djk154.; Olin RL, Desai SS, Fox K, Davidson R. Non-myopathic cardiac events in two patients treated with trastuzumab. Breast J. 2007;13(2):211-2. DOI:10.1111/j.1524-4741.2007.00408.x.; Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009;100(5):684-92. DOI:10.1038/sj.bjc.6604909.; Kupari M, Volin L, Suokas A, et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990;5(2):91-8.; Yang X, Li X, Yuan M, et al. Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front Pharmacol. 2018;9:1058. DOI:10.3389/fphar.2018.01058.; Aziz SA, Tramboo NA, Mohi-ud-Din K, et al. Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. Clin Oncol (R Coll Radiol). 1998;10(6):377-8. DOI:10.1016/s0936-6555(98)80033-2.; Meydan N, Kundak I, Yavuzsen T, et al. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol. 2005;35(5):265-70. DOI:10.1093/jjco/hyi071.; Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24(7):1072-8. DOI:10.1200/JCO.2004.00.1792.; Ifran A, Kaptan K, Beyan C. High-dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation. Am J Hematol. 2005;80(3):247. DOI:10.1002/ajh.20441.; Bischiniotis TS, Lafaras CT, Platogiannis DN, et al. Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Hellenic J Cardiol. 2005;46(5):324-9.; Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol. 1988;13(1):41-6. DOI:10.1016/0167-8140(88)90296-4.; Menard O, Martinet Y, Lamy P. Cisplatin-induced atrial fibrillation. J Clin Oncol. 1991;9(1):192-3. DOI:10.1200/JCO.1991.9.1.192.; Tomkowski WZ, Wiśniewska J, Szturmowicz M, et al. Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer. 2004;12(1):53-7. DOI:10.1007/s00520-003-0533-x.; Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138(2):405-11. DOI:10.1016/j.jtcvs.2009.02.046.; Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24(10):1561-7. DOI:10.1200/JCO.2005.04.6813.; Zellos L, Richards WG, Capalbo L, et al. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostinecytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009;137(2):453-8. DOI:10.1016/j.jtcvs.2008.07.055.; Patel AK, Skatrud JB, Thomsen JH. Cardiac Arrhythmias Due to Oral Aminophylline in Patients With Chronic Obstructive Pulmonary Disease. Chest. 1981;80(6):661-5. DOI:10.1378/chest.80. 6.661.; Varriale P, Ramaprasad S. Aminophylline Induced Atrial Fibrillation. Pacing Clin Electrophysiol. 1993;16(10):1953-5. DOI:10.1111/j.1540-8159.1993.tb00987.x.; Chazan R, Karwat K, Tyminska K, et al. Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction. Int J Clin Pharmacol Ther. 1995;33(3):170-5.; Henderson A, Wright DM, Pond SM. Management of Theophylline Overdose Patients in the Intensive Care Unit. Anaesth Intensive Care. 1992;20(1):56-62. DOI:10.1177/0310057X9202000111.; Okada S, Teramoto S, Matsuoka R. Recovery From Theophylline Toxicity by Continuous Hemodialysis With Filtratio. Ann Intern Med. 2000;133(11):922. DOI:10.7326/0003-4819-133-11-200012050-00024.; Poukkula A, Korhonen UR, Huikuri H, Linnaluoto M. Theophylline and Salbutamol in Combination in Patients With Obstructive Pulmonary Disease and Concurrent Heart Disease: Effect on Cardiac Arrhythmias. J Intern Med. 1989;226(4):229-34. DOI:10.1111/j.1365-2796.1989.tb01385.x.; Raoof S, Wollschlager C, Khan FA. Ciprofloxacin increases serum levels of theophylline. Am J Med. 1987;82(4A):115-8.; Holden R. Probable fatal interaction between ciprofloxacin and theophylline. BMJ. 1988;297(6659):1339. DOI:10.1136/bmj.297.6659.1339.; Richardson JP. Theophylline Toxicity Associated With the Administration of Ciprofloxacin in a Nursing Home Patient. J Am Geriatr Soc. 1990;38(3):236-8. DOI:10.1111/j.1532-5415.1990.tb03497.x.; O' Driscoll BR. Supraventricular tachycardia caused by nebulized ipratropium bromide. Thorax. 1989;44(4):312. DOI:10.1136/thx.44.4.312.; Daubert GP, Mabasa VH, Leung VW, Aaron C. Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. J Med Toxicol. 2007;3(2):56-60. DOI:10.1007/BF03160909.; MacMahon JR. Atrial fibrillation and sympathomimetics (letter). J Pediatr. 1974;84(4):613. DOI:10.1016/s0022-3476(74)80701-8.; Patane S, Marte F, La Rosa FC, La Rocca R. Atrial fibrillation associated with chocolate intake abuse and chronic salbutamol inhalation abuse. Int J Cardiol. 2010;145(2):e74-6. DOI:10.1016/j.ijcard.2008.12.159.; Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore). 2008;87(6):319-28. DOI:10.1097/MD.0b013e31818fcc02.; Michele J, Stephan FL, Wentworth C 3rd, et al. Comparative Safety of Long-Acting Inhaled Bronchodilators: A Cohort Study Using the UK THIN Primary Care Database. Drug Saf. 2007;30(12):1151-60. DOI:10.2165/00002018-200730120-00007.; Veloso HH, de Paola AAV. Atrial fibrillation after vardenafil therapy. Emerg Med J. 2005;22(11):823. DOI:10.1136/emj.2004.015982.; Frederiksen MC, Toig RM, Depp R. III. Atrial fibrillation during hexoprenaline therapy for premature labor. Am J Obstet Gynecol. 1983;145(1):108-9. DOI:1016/0002-9378(83)90350-2.; Varkey S. Overdose of yohimbine. BMJ. 1992;304(6826):548. DOI:10.1136/bmj.304.6826.548-a.; Hayashi K, Minezaki KK, Narukawa M, et al. Atrial fibrillation and continuous 161. hypotension induced by sildenafil in an intermittent WPW syndrome patient. Jpn Heart J. 1999;40(6):827-30. DOI:10.1536/jhj.40.827.; Awan GM, Calderon E, Dawood G, Alpert MA. Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy. Am J Med Sci. 2000;320(1):69-71. DOI:10.1097/00000441-200007000-00011.; Cassinotti A, Massari A, Ferrara E., et al. New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. Eur J Clin Pharmacol. 2007;63(9):875-8. DOI:10.1007/s00228-007-0328-y.; Riccioni G, Bucciarelli V, Di Ilio E, et al. Recurrent atrial fibrillation in a patient with ulcerative colitis treated with azathioprine: case report and review of the literature. Int J Immunopathol Pharmacol. 2011;24(1):247-9. DOI:10.1177/039463201102400131.; Dodd HJ, Tatnall FM, Sarkany I. Fast atrial fibrillation induced by treatment of psoriasis with azathioprine. Br Med J (Clin Res Ed). 1985;291(6497):706. DOI:10.1136/bmj.291.6497.706.; Wooten MD, Reddy GV, Johnson RD. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J. 2000;72(12):517-19.; Paolicelli D, Manni A, Direnzo V, et al. Long-term Cardiac Safety and Tolerability of Fingolimod in Multiple Sclerosis: A Postmarketing Study. J Clin Pharmacol. 2015;55(10):1131-6. DOI:10.1002/jcph.519.; Rolf L, Muris A, Damoiseaux J, et al. Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment. Neurology 2014;82(11):1008-9. DOI:10.1212/WNL.0000000000000218.; Wallemacq PE, Lesne ML. Accidental massive IV administration of cyclosporine in man. Drug Intell Clin Pharm, 1985;19(1):29-30. DOI:10.1177/106002808501900106.; LoVecchio FA, Goltz HR. Atrial fibrillation following acute overdose with oral cyclosporine. Ann Pharmacother. 2000;34(3):405. DOI:10.1345/aph.19134.; Pratila MG, Pratilas V. Dysrhythmia occurring during epidural anesthesia with bupivacaine. The Mt Sinai J Med. 1982;49(2):130-2.; Heckbert S, Guo L, Steven RC, et al. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women. Arch Intern Med. 2008;168(8):826-31. DOI:10.1001/archinte.168.8.826.; Grosso A, Douglas I, Hingorani A. Oral Bisphosphonates and Risk of Atrial Fibrillation and Flutter in Women: A Self-Controlled Case-Series Safety Analysis. PLoS One. 2009;4(3):e4720. DOI:10.1371/journal.pone.0004720.; Herrera L, Leal I, Lapi F, et al. Risk of Atrial Fibrillation Among Bisphosphonate Users: A Multicenter, Population-Based, Italian Study. Osteoporosis Int. 2015;26(5):1499-506. DOI:10.1007/s00198-014-3020-y.; Black DM, Reiss TF, Nevitt MC, et al. Design of the Fracture Intervention Trial. Osteoporosis Int. 1993;3(3):S29-S39. DOI:10.1007/BF01623005.; Black DM, Delmas PD, Eastell R, et al. Once-yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007;356(18):1809-22. DOI:10.1056/NEJMoa067312.; Konsta M, Bournia VK, Dania V, Iliopoulos A. Atrial Fibrillation Following Intravenous Zolendronic Acid for Osteoporosis. J Clin Rheumatol. 2014;20(4):239-40. DOI:10.1097/RHU.0000000000000114.; Lau DH, Stiles MK, John B, et al. Atrial fibrillation and anabolic steroid abuse. Int J Cardiol. 2007;117(2):e86-7. DOI:10.1016/j.ijcard.2006.11.199.; Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med. 1999;17(5):851-7. DOI:10.1016/s0736-4679(99)00095-5.; Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr. 2005;81(3):578-82. DOI:10.1093/ajcn/81.3.578.; Choragudi NL, Aronow WS, DeLuca AJ. Nicotine gum-induced atrial fibrillation. Heart Dis. 2003;5(2):100-1. DOI:1010.1097/01.hdx.0000061700.11321.1a.; Stewart PM, Catterall JR. Chronic nicotine ingestion and atrial fibrillation. Br Heart J. 1985;54(2):222-3. DOI:10.1136/hrt.54.2.222.; Rigotti NA, Eagle KA. Atrial fibrillation while chewing nicotine gum. JAMA 1986;255(8):1018.; Craig TJ, Samuel LW, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-76. DOI:10.1016/j.jacc.2014.03.022.; Smeets JL, Allessie MA, Lammers WJ, et al. The Wavelength of the Cardiac Impulse and Reentrant Arrhythmias in Isolated Rabbit Atrium. The Role of Heart Rate, Autonomic Transmitters, Temperature, and Potassium. Circ Res. 1986;58(1):96-108. DOI:10.1161/01.res.58.1.96.; Rensma PL, Allessie MA, Lammers WJ, et al. Length of Excitation Wave and Susceptibility to Reentrant Atrial Arrhythmias in Normal Conscious Dogs. Circ Res. 1988;62(2):395-410. DOI:10.1161/01.res.62.2.395.; Wakili R, Voigt N, Kaab S, et al. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121(8):2955-68. DOI:10.1172/JCI46315.; Ogawa M, Zhou S, Tan AY, et al. Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol. 2007;50(4):335-43. DOI:10.1016/j.jacc.2007.03.045.; Chen PS, Douglas P. Zipes Lecture. Neural mechanisms of atrial fibrillation. Heart Rhythm. 2006;3(11):1373-7. DOI:10.1016/j.hrthm.2006.08.010.; Zhou S, Chang CM, Wu TJ, et al. Nonreentrant focal activations in pulmonary veins in canine model of sustained atrial fibrillation. Am J Physiol Heart Circ Physiol. 2002;283(3):H1244–H1252. DOI:10.1152/ajpheart.01109.2001.; Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale based combined treatments against cancer. Cell Death Differ. 2014;21(1):1525. DOI:10.1038/cdd.2013.67.; Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63(10):945-53. DOI:10.1016/j.jacc.2013.11.026.; Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1(1):62-73. DOI:10.1161/CIRCEP.107.754564.; Hove-Madsen L, Llach A, Bayes-Genis A, et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation. 2004;110(11):1358-63. DOI:10.1161/01.CIR.0000141296.59876.87.; Vest JA, Wehrens XH, Reiken SR, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation. 2005;111(16):2025-32. DOI:10.1161/01.CIR.0000162461.67140.4C.; Chelu MG, Sarma S, Sood S, et al. Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest. 2009;119(7):1940-51. DOI:10.1172/jci37059.; Neef S, Dybkova N, Sossalla S, et al. CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res. 2010;106(6): 1134-44. DOI:10.1161/CIRCRESAHA.109.203836.; Dobrev D, Voigt N, Wehrens X H. The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res. 2011;89(4):734-43. DOI:10.1093/cvr/cvq324.; Voigt N, Heijman J, Wang Q, et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation. 2014;129(2):145-56. DOI:10.1161/CIRCULATIONAHA.113.006641.; Voigt N, Li N, Wang Q, et al. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation. 2012;125(17):2059-70. DOI:10.1161/CIRCULATIONAHA.111.067306.; Xing Y, Gao Y, Chen J, et al. Wenxin-Keli regulates the calcium/calmodulin-dependent protein kinase ii signal transduction pathway and inhibits cardiac arrhythmia in rats with myocardial infarction. Evid Based Complement Alternat Med. 2013;2013:464508. DOI:10.1155/2013/464508.; Yang X, Yu C, Li Y, et al. Effects of Wenxin Keli on cardiac hypertrophy and arrhythmia via regulation of the calcium/calmodulin dependent kinase ii signaling pathway. BioMed Res Int. 2017;2017:1569235. DOI:10.1155/2017/1569235.; Sag CM, Köhler AC, Anderson ME, et al. CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol. 2011;51(5):749-59. DOI:10.1016/j.yjmcc.2011.07.016.; Давтян К.В., Калемберг А.А., Царева Е.Н., и др. Роль воспалительной теории в патогенезе фибрилляции предсердий. Российский Кардиологический Журнал 2019;24(7):110-4. DOI:10.15829/1560-4071-2019-7-110-114.; Gedikli O, Dogan A, Altuntas I, et al. Inflammatory markers according to types of atrial fibrillation. Int J Cardiol. 2007;120(2):193-7. DOI:10.1016/j.ijcard.2006.09.015.; Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J. 2004;148(3):462-6. DOI:10.1016/j.ahj.2004.01.026.; Guzzetti S, Costantino G, Fundaro C. Systemic inflammation, atrial fibrillation, and cancer. Circulation. 2002;106(9):e40. DOI:10.1161/01.cir.0000028399.42411.13.; Wang ZX, Wang HQ, Cheng J, et al. Research progress on pathogenesis of atrial fibrillation. China Medical Herald. 2018;15;26-9.; Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25. DOI:10.1093/jnci/djp44.; Liu Y, Tan D, Shi L, et al. Blueberry anthocyaninsenriched extracts attenuate cyclophosphamide-induced cardiac injury. PLoS ONE. 2015 2;10(7):e0127813. DOI:10.1371/journal.pone.0127813.; Gu JF. The research progress on cardiac toxic mechanism of anthracyclines and prevention treatment measures. World Notes Antibiot. 2015;6:241-8. DOI:10.13461/j.cnki.wna.004903.; Yang X, Li Y, Li Y, et al. Oxidative stress-mediated atherosclerosis: mechanisms and therapies. Front Physiol. 2017;8:600. DOI:10.3389/fphys.2017.00600.; O’Neal WT, Lakoski SG, Qureshi W, et al. Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). Am J Cardiol. 2015;115(8):1090-4. DOI:10.1016/j.amjcard.2015.01.540.; Samman TA, Sandesara PB, Hayek SS, et al. Association between oxidative stress and atrial fibrillation. Heart Rhythm. 2017;14(12):1849-55. DOI:10.1016/j.hrthm.2017.07.028.; Beck MA. Selenium and host defence towards viruses. Proc Nutr Soc. 1999;58(3):707-11. DOI:10.1017/s0029665199000920.; Ozaki M, Deshpande SS, Angkeow P, et al. Inhibition of the Rac1 GTPase protects against nonlethal ischemia/reperfusion-induced necrosis and apoptosis in vivo. FASEB J. 2000;14(2):418-29. DOI:10.1096/fasebj.14.2.418.; Keefe DL Anthracyciine-Induced cardiomyopathy. Seminars in oncology 2001;28(4 suppl 12):2-7. DOI:10.1053/sonc.2001.26431.; Gen W, Tani M, Takeshita J, et al. Mechanisms of Ca2+ overioad induced by extracellular H2O2 in quiescent isoiated rat cardiomyocytes. Basic Res Cardiol. 2001;96(6):623-9. DOI:10.1007/s003950170014.; Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233. DOI:10.1161/CIR.0000000000000905.; Breeden CC, Safirstein BH. Spacer-induced Atrial Fibrillation. N J Med. 1990;87(2):113-4.; Сычев Д.А., Остроумова О.Д., Переверзев А.П., и др. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020;27(6):113-26. DOI:10.18565/pharmateca.2020.6.113-126.; Phillips BG, Gandhi AJ, Sanoski CA, et al. Comparison of Intravenous Diltiazem and Verapamil for the Acute Treatment of Atrial Fibrillation and Atrial Flutter. Pharmacotherapy. 1997;17(6):1238-45.; Minton NA, Henry JA. Treatment of Theophylline Overdose. Am J Emerg Med. 1996;14(6):606-12. DOI:10.1016/S0735-6757(96)90111-4.; Lancellotti P, Suter TM, López-Fernández T, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019;40(22):1756-63. DOI:10.1093/eurheartj/ehy453.; Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676. DOI:10.1093/europace/euab065.; Sychev D, Mirzaev K, Cherniaeva M, et al. Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. Drug Metab Pers Ther. 2020;35(3). DOI:10.1515/dmpt-2020-0127.; https://www.rpcardio.com/jour/article/view/2636
-
14Academic Journal
Authors: N. V. Orlovа, O. D. Ostroumovа, E. V. Shikh, S. V. Smerdin, E. V. Rebrovа, V. А. Dyo, Н. В. Орлова, О. Д. Остроумова, Е. В. Ших, С. В. Смердин, Е. В. Реброва, В. А. Дё
Source: Tuberculosis and Lung Diseases; Том 99, № 7 (2021); 55-62 ; Туберкулез и болезни легких; Том 99, № 7 (2021); 55-62 ; 2542-1506 ; 2075-1230
Subject Terms: нежелательные лекарственные реакции, antineoplastic therapy, pneumotoxicity, adverse drug reactions, противоопухолевая терапия, пневмотоксичность
File Description: application/pdf
Relation: https://www.tibl-journal.com/jour/article/view/1556/1559; Анаев Э. Х. Лекарственно-индуцированное интерстициальное заболевание легких: подходы к диагностике и лечению // Терапевтический архив. – 2020. – Т. 92, № 3. – С. 84-91.; Майорова О. А. Фармакогенетика: индивидуальные особенности метаболизма // Качественная клиническая практика. ‒ 2002. ‒ № 4. – С. 2-10.; Постников С. С., Грацианская А. Н., Костылева М. Н. Лекарственная патология легких // Педиатрия. Журнал им. Г. Н. Сперанского. ‒ 2013. ‒ № 92 (3). ‒ С. 130-135.; Сычев Д. А., Остроумова О. Д., Переверзев А. П., Кочетков А. И., Остроумова Т. М., Клепикова М. В., Аляутдинова И. А., Голобородова И. В. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике // Фармаконадзор. Фарматека. ‒ 2020. ‒ № 27 (6). ‒ С. 113-126.; Abdel-Rahman O., Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis // Ther. Adv. Respir. Dis. ‒ 2016. ‒ № 10. – Р. 183-193.; Albrecht E., Bayon V., Hirotsu C., Al Ja'bari A., Heinzer R. Intrathecal morphine and sleep apnoea severity in patients undergoing hip arthroplasty: a randomised, controlled, triple-blinded trial // Br. J. Anaesth. ‒ 2020. ‒ № 125 (5). – Р. 811-817.; Anan K., Ichikado K., Kawamura K. Clinical characteristics and prognosis of drug-associated acute respiratory distress syndrome compared with non-drug-associated acute respiratory distress syndrome: a single-centre retrospective study in Japan // BMJ Open. – 2017. ‒ № 7. ‒ Р. e015330.; Ananthakrishnan A. N., Attila T., Otterson M. F., Lipchik R. J., Massey B. T., Komorowski R. A., Binion D. G. Severe pulmonary toxicity after azathioprine/6- mercaptopurine initiation for the treatment of inflammatory bowel disease // J. Clin. Gastroenterol. ‒ 2007. ‒ № 41. – Р. 682-688.; Ando S. S., Kawai K. K., Kuriyagawa K. K., Sekido N., Miyanaga N., Shimazui T., Akaza H. Extremely acute exacerbation of interstitial pneumonia after interferonalpha treatment for metastatic renal cell carcinoma // Int. J. Clin. Oncol. ‒ 2009. ‒ Vol. 14, № 2. – Р. 171-173.; Ando M., Okamoto I., Yamamoto N., Takeda K., Tamura K., Seto T., Ariyoshi Y., Fukuoka M. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib // Clin. Oncol. – 2006. – № 24 (16). – P. 2549-2556.; Balk R. A. Methotrexate-induced lung injury // Wolters Kluwer. – 2020 Nov. Available from: https://www.uptodate.com/contents/methotrexate-inducedlung-injury.; Bonniaud P., Georges M., Favrolt N., Camus P. [Drug-induced interstitial lung diseases] // Rev Prat. ‒ 2014. ‒ № 64. ‒ Р. 951.; Camus P., von der Thüsen J., Hansell D. M., Colby T. V. Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs? // Eur. Respir. J. ‒ 2014. ‒ № 44. ‒ Р. 289.; Cao T. M., Negrin R. S., Stockerl-Goldstein K. E., Johnston L. J., Shizuru J. A., Taylor T. L., Rizk N. W., Wong R. M., Blume K. G., Hu W. W. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation // Biol. Blood Marrow Transplant. ‒ 2000. ‒ № 6 (4). – Р. 387-394.; Charpidou A. G., Gkiozos I., Tsimpoukis S., Apostolaki D., Dilana K. D., Karapanagiotou E. M., Syrigos K. N. Therapy-induced Toxicity of the Lungs: An Overview // Anticancer Research. – 2009. – № 29. – P. 631-640.; Das B., Shoemaker L., Subramanian S., Johnsrude C., Recto M., Austin E. Acute sirolimus pulmonary toxicity in an infant heart transplant recipient: case report and literature review // J. Heart Lung Transplant. ‒ 2007. ‒ № 26. – Р. 296-298.; Dhokarh R., Li G., Schmickl C. N. et al. Drug-associated acute lung injury: a population-based cohort study // Chest. ‒ 2012. ‒ № 142. ‒ Р. 845.; Dimopoulou I., Bamias A., Lyberopoulos P., Dimopoulos M. A. Pulmonary toxicity from novel antineoplastic agents // Ann. Oncol. ‒ 2006. ‒ № 17 (3). – Р. 372-379.; Duley J. A., Marinaki A. M., Arenas M., Florin T. H. J. Do ITPA and TPMT genotypes predict the development of side effects to AZA? // Gut. ‒ 2006. ‒ Vol. 55, № 7. – Р. 1048.; El-Melouk W., Jazieh A. R. Novel drug-induced pulmonary complications in cancer patients you can save life! // Current Respiratory Medicine Reviews. – 2016. ‒ № 12 (2).; Fabien Maldonado F., Limper A. H., Cass A. S. Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment // https://www.uptodate.com/contents/pulmonary-toxicity-associated-with-systemic-antineoplastic-therapy-clinical-presentation-diagnosis-and-treatment.; Froudarakis M., Hatzimichael E., Kyriazopoulou L., Lagos K., Pappas P., Tzakos A. G., Karavasilis V., Daliani D., Papandreou Ch., Briasoulis E. Revisiting bleomycin from pathophysiology to safe clinical use // Crit. Rev. Oncol. Hematol. ‒ 2013. ‒ № 87 (1). – Р. 90-100.; Fujimoto D., Kato R., Morimoto T. et al. Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer // PLoS One. ‒ 2016. ‒ № 11. ‒ Р. e0168465.; Haston C., Wang M. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice // Human Molecular Genetics. ‒ 2002. ‒ № 11 (16). – Р. 1855-1863.; Hayslip J., Fenning R. Safe administration of iodine-131 tositumo-mab after repeated infusion-related reactions to rituximab // Oncologist. ‒ 2007. ‒ № 12. – Р. 338-340.; Hecht J. R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., Marshall J., Cohn A., McCollum D., Stella P., Deeter R., Shahin S., Amado R. G. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer // J. Clin. Oncol. ‒ 2009. ‒ № 27. – Р. 672-680.; Heit J. A., Silverstein M. D., Mohr D. N., Petterson T. M., O'Fallon W. M., Melton 3rd. L. J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study // Arch. Intern. Med. ‒ 2000. – № 160. – Р. 809-815.; Howell A., Pippen J., Elledge R. M., Mauriac L., Vergote I., Jones S. E., Come S. E., Osborne C. K., Robertson J. F. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials // Cancer. ‒ 2005. ‒ № 104. – Р. 236-239.; Imokawa S., Colby T. V., Leslie K. O., Helmers R. A. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients // Eur. Respir. J. ‒ 2000. ‒ № 15. – Р. 373-381.; Inomata S., Takahashi H., Nagata M., Yamada G., Shiratori M., Tanaka H., Satoh M., Saitoh T., Sato T., Abe S. Acute lung injury as an adverse event of gefitinib // Anticancer Drugs. ‒ 2004. ‒ № 15. – Р. 461-467.; Inoue A., Sugawara S., Yamazaki K., Maemondo M., Suzuki T., Gomi K., Takanashi Sh., Inoue Ch., Inage M., Yokouchi H., Watanabe H., Tsukamoto T., Saijo Ya., Ishimoto O., Hommura F., Nukiwa T. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402 // J. Clin. Oncol. ‒ 2008. ‒ № 26. – Р. 5401.; Jóna Á., Miltényi Z., Póliska S., Bálint B. L., Illés Á. Effect of Bleomycin Hydrolase Gene Polymorphism on Late Pulmonary Complications of Treatment for Hodgkin Lymphoma // PLOS One. ‒ 2016. ‒ № 11 (6). ‒ Р. е0157651.; Kinder A. J., Hassell A. B., Brand J., Brownfield A., Grove M., Shadforth M. F. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions // Rheumatology. ‒ 2005. ‒ № 44. – Р. 61-66.; Konstantinides S., Meyer G., Becattini C., Bueno H., Geersing G-J., Harjola V. P., Huisman Menno V, Humbert M., Jennings C.S., Jiménez D., Kucher N., Lang I. M., Lankeit M., Lorusso R., Mazzolai L., Meneveau N., Áinle F. N., Prandoni P., Pruszczyk P., Righini M., Torbicki A., Belle E. V., Zamorano J. L. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) // Eur. Heart J. ‒ 2020. ‒ № 41. – Р. 543-603.; Kumar S., Mehra S. How drugs affect the lungs // Internet J. Pulm. Med. ‒ 2008. ‒ Vol. 9, № 2. – Р. 1-5.; Leader W. G., Mohundro B. L. Asthma and bronchospasm. drug induced diseases: prevention, detection, and management. 2nd ed. // Am. Soc. Health-System Pharmac. ‒ 2010. ‒ Chap. 22. – Р. 378-397.; Lee M.-Y., Yoon S. Y., Kim K. H., Lee N., Kim H. Y., Hwang J. H., Jong-Ho Won J.-H. Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience // Korean J. Intern. Med. – 2021. – P. 1-10.; Leger P., Limper A. H., Maldonado F. Pulmonary toxicities from conventional chemotherapy // Clin. Chest Med. ‒ 2017. ‒ № 38. ‒ Р. 209.; Li X., Shan B-E., Wang J., Xing L-P., Guo X-J., Zhang Y-H., Shi P-H., Wang Z-Y. Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials // PLoS One. ‒ 2013. ‒ № 8 (11). ‒ Р. e81897.; Limper A.H. Chemotherapy-induced lung disease // Clin. Chest Med. ‒ 2004. ‒ № 25. – Р. 53.; Liote H., Liote F., Seroussi B., Mayaud C., Cadranel J. Rituximab-induced lung disease: A systematic literature review // Eur. Respir. J. ‒ 2010. ‒ № 35. – Р. 681-687.; Martin W. G., Ristow K. M., Habermann T. M., Colgan J. P., Witzig Th. E., Ansell S. E. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma // J. Clin. Oncol. ‒ 2005. ‒ № 23 (30). – Р. 7614-7620.; Matsumoto K., Nakao S., Hasegawa S., Matsui T., Shimada K., Mukai R., Tanaka M., Uranishi H., Nakamura M. Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database // SAGE. ‒ 2020. ‒ № 8. ‒ 2050312120918264.; Nebeker J. R., Barach P., Samore M. H. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting // Ann. Intern. Med. ‒ 2004. ‒ № 140. ‒ Р. 795.; Nivetha R., Arul B., Kothai R. Drug Induced Pulmonary Disease-A Mini Review // Research J. Pharm. and Tech. – 2019. – № 12 (9). – P. 4583-4588.; O'Sullivan J. M., Huddart R. A., Norman A. R., Nicholls J., Dearnaley D. P., Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours // Ann. Oncology. ‒ 2003. ‒ Vol. 14, № 1. ‒ Р. 91-96.; Ozkan М., Dweik R. A. Drug-induced lung disease // Clevel. Clin. J. Med. ‒ 2001. ‒ № 68 (9). – Р. 782-795.; Possick J. D. Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy // Clin. Chest Med. ‒ 2017. ‒ № 38. ‒ Р. 223.; Rosenow 3rd E. C. Drug-induced pulmonary disease // Dis. Mon. ‒ 1994. ‒ № 40. – Р. 253-310.; Ryu J. H. Chemotherapy-induced pulmonary toxicity in lung cancer patients // J. Thorac. Oncol. ‒ 2010. ‒ № 5. – Р. 1313.; Starling N., Rao S., Cunningham D., Iveson T., Nicolson M., Coxon F., Middleton G., Daniel F., Oates J., Norman A.R. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group // J. Clin. Oncol. ‒ 2009. ‒ № 27. – Р. 3786-3793.; Takahashi H., Fujishima T., Koba H., Murakami S., Kurokawa K., Shibuya Y., Shiratori M, Kuroki Y., Abe S. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent // Am. J. Respir. Crit. Care Med. ‒ 2000. ‒ № 162. – Р. 1109-1114.; Tamura M., Saraya T., Fujiwara M., Hiraoka S., Yokoyama T., Yano K., Ishii H., Furuse J., Goya T., Takizawa H., Goto H. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases // Oncologist. ‒ 2013. ‒ № 18 (4). – Р. 454.; Torrisi J. M., Schwartz L. H., Gollub M. J., Ginsberg M. S., Bosl G. J., Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity // Radiology. ‒ 2011. ‒ № 258(1). – Р. 41-56.; Vahid B., Marik P. E. Pulmonary complications of novel antineoplastic agents for solid tumors // Chest. ‒ 2008. ‒ № 133. – Р. 528-538.; Vander Els. N. J., Stover D. E. Chemotherapy-Induced Lung Disease // Clin. Pulmon. Med. ‒ 2004. – Vol. 11, № 2. – Р. 84-91.; Zarogoulidis P., Chatzaki E., Porpodis K., Domvri K., Hohenforst-Schmidt W., Goldberg E. P., Karamanos N., Zarogoulidis K. Inhaled chemotherapy in lung cancer: Future concept of nanomedicine // Int. J. Nanomed. ‒ 2012. ‒ № 7. – Р. 1551-1572.
-
15Academic Journal
Authors: E. V. Zakharova, O. D. Ostroumova, M. V. Klepikova, Е. В. Захарова, О. Д. Остроумова, М. В. Клепикова
Contributors: The study was performed without external funding., Работа выполнена без спонсорской поддержки.
Source: Safety and Risk of Pharmacotherapy; Том 9, № 3 (2021); 117-127 ; Безопасность и риск фармакотерапии; Том 9, № 3 (2021); 117-127 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2021-9-3
Subject Terms: противоопухолевые препараты, drugs, adverse drug reactions, antibiotics, renin-angiotensin-aldosterone system inhibitors, non-steroidal anti-inflammatory drugs, anticancer drugs, лекарственные средства, нежелательные лекарственные реакции, антибиотики, блокаторы ренин-ангиотензин-альдостероновой системы, нестероидные противовоспалительные препараты
File Description: application/pdf
Relation: https://www.risksafety.ru/jour/article/view/228/358; https://www.risksafety.ru/jour/article/downloadSuppFile/228/174; https://www.risksafety.ru/jour/article/downloadSuppFile/228/175; https://www.risksafety.ru/jour/article/downloadSuppFile/228/185; https://www.risksafety.ru/jour/article/downloadSuppFile/228/192; Cмирнов АВ, Добронравов ВА, Румянцев АШ, Шилов ЕМ, Ватазин АВ, Каюков ИГ и др. Национальные рекомендации. Острое повреждение почек: основные принципы диагностики, профилактики и терапии. Часть I. Нефрология. 2016;20(1):79–104.; Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–126. https://doi.org/10.1038/kisup.2012.8; Ghane SF, Assadi F. Drug-induced renal disorders. J Renal Inj Prev. 2015;4(3):57–60. https://doi.org/10.12861/jrip.2015.12; Sales G, Foresto R. Drug-induced nephrotoxicity. Rev Assoc Med Bras. 2020;66(Suppl. 1):82–90. https://doi.org/10.1590/1806-9282.66.S1.82; Petejova N, Martinek A, Zadrazil J, Teplan V. Acute toxic kidney injury. Ren Fail. 2019;41(1):576–94. https://doi:10.1080/0886022X.2019.1628780; Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–6. https://doi.org/10.1053/ajkd.2002.32766; Schetz M, Dasta J, Goldstein S, Golper T. Drug induced acute kidney injury. Curr Opin Crit Care. 2005;11(6):555–65. https://doi.org/10.1097/01.ccx.0000184300.68383.95; Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, Macleod A. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol. 2007;18(4):1292–8. https://doi.org/10.1681/ASN.2006070756; Wang HE, Muntner P, Chertow GM, Warnock DG. Acute kidney injury and mortality in hospitalized patients. Am J Nephrol. 2012;35(4):349–55. https://doi.org/10.1159/000337487; Thakar CV, Christianson A, Freyberg R, Almenoff P, Render M. Incidence and outcomes of acute kidney injury in intensive care units: a Veterans Administration study. Crit Care Med. 2009;37(9):2552–8. https://doi.org/10.1097/ccm.0b013e3181a5906f; Смирнов АВ, Румянцев АШ. Острое повреждение почек. Часть I. Нефрология. 2020;24(1):67–95.; Kane-Gill SL, Goldstein SL. Drug-induced acute kidney injury: a focus on risk assessment for prevention. Crit Care Clin. 2015;31(4):675–84. https://doi.org/10.1016/j.ccc.2015.06.005; Ympa YP, Sakr Y, Reinhart K, Vincent JL. Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med. 2005;118(8):827–32. https://doi.org/10.1016/j.amjmed.2005.01.069; Gruberg L, Weissman NJ, Pichard AD, Waksman R, Kent KM, Satler LF, et al. Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. Am Heart J. 2003;145(3):529–34. https://doi.org/10.1067/mhj.2003.121; Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–8. https://doi.org/10.1001/jama.294.7.813; Anathhanam S, Lewington AJP. Acute kidney injury. J R Coll Physicians Edinb. 2013;43(4):323–8. https://doi.org/10.4997/jrcpe.2013.412; Mehta RL, Awdishu L, Davenport A, Murray P, Macedo E, Cerda J, et al. Phenotype standardization for drug-induced kidney disease. Kidney Int. 2015;88(2):226–34. https://doi.org/10.1038/ki.2015.115; Izzedine H, Perazella MA. Anticancer drug-induced acute kidney injury. Kidney Int Rep. 2017;2(4):504–14. https://doi.org/10.1016/j.ekir.2017.02.008; Perazella MA. Update on the renal effects of anticancer agents. J Onco-Nephrol. 2017;1(3):170–8. https://doi.org/10.5301/jo-n.5000026; Chemotherapy and radiation related kidney diseases. In: Finkel KW, Perazella MA, Cohen EP, eds. Onco-Nephrology. Elsevier; 2020. Section 4. P. 127–96.; Paueksakon P, Fogo AB. Drug-induced nephropathies. Histopathology. 2017;70(1):94–108. https://doi.org/10.1111/his.13064; Jackson B, Matthews PG, McGrath BP, Johnston CI. Angiotensin converting enzyme inhibition in renovascular hypertension: frequency of reversible renal failure. Lancet. 1984;1(8370):225–6. https://doi.org/10.1016/s0140-6736(84)92149-4; Mason NA. Angiotensin-converting enzyme inhibitors and renal function. DICP. 1990;24(5):496–505. https://doi.org/10.1177/106002809002400511; Whelton A, Hamilton CW. Non-steroidal anti inflammatory drugs: effects on kidney function. Clin Pharmacol. 1991;31(7):588–98. https://doi.org/10.1002/j.1552-4604.1991.tb03743.x; Goli R, Mukku KK, Devaraju SB, Uppin MS. Acyclovir-induced thrombotic microangiopathy. Indian J Nephrol. 2017;27(2):131–2. https://doi.org/10.4103/0971-4065.181453; Rey A, Batteux B, Laville SM, Marienne J, Masmoudi K, Gras-Champel V, Liabeuf S. Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study. Arthritis Res Ther. 2019;21(1):229. https://doi.org/10.1186/s13075-019-2011-y; Leowattana W. Antiviral drugs and acute kidney injury (AKI). Infect Disord Drug Targets. 2019;19(4):375–82. https://doi:10.2174/1871526519666190617154137; Kim YG, Kim B, Kim MK, Chung SJ, Han HJ, Ryu JA, et al. Medullary nephrocalcinosis associated with long-term furosemide abuse in adults. Nephrol Dial Transplant. 2001;16(12):2303–9. https://doi:10.1093/ndt/16.12.2303; Gagnon RF, Mehio A, Iqbal S, Tsoukas CM. Néphropathie tubulo-interstitielle associée à l’indinavir. Nephrol Ther. 2007;3(7):461–2. https://doi.org/10.1016/j.nephro.2007.07.004; Wu D, Stoller ML. Indinavir urolithiasis. Curr Opin Urol. 2000;10(6):557–61. https://doi.org/10.1097/00042307-200011000-00004; Lamb EJ, Nashef L, Stevens PE. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem. 2004;41(Pt 2):166–9. https://doi.org/10.1258/000456304322880104; de la Prada Alvarez FJ, Prados Gallardo AM, Tugores Vázquez A, Uriol Rivera M, Morey Molina A. Insuficiencia renal aguda por depósito de cristales de Sulfadiacina. An Med Interna. 2007;24(5):235–8.; Kubota M, Nishi-Nagase M, Sakakihara Y, Noma S, Nakamoto M, Kawaguchi H, et al. Zonisamide-induced urinary lithiasis in patients with intractable epilepsy. Brain Dev. 2000;22(4):230–3. https://doi.org/10.1016/s0387-7604(00)00118-2; Ram R, Swarnalatha G, Prasad N, Prayaga A, Dakshina Murthy KV. Granulomatous interstitial nephritis after prolonged use of phenytoin. Saudi J Kidney Dis Transpl. 2009;20(1):131–3.; Torregrosa E, Rovira RE, Calvo C, Hernández-Jaras J, Maduell F, García H. Nefritis intersticial aguda por omeprazol. Nefrologia. 2004;24 Suppl 3:61–3.; Muthukumar T, Jayakumar M, Fernando EM, Muthusethupathi M. Acute renal failure due to rifampicin: a study of 25 patients. Am J Kidney Dis. 2002;40(4):690–6. https://doi.org/10.1053/ajkd.2002.35675; Enríquez R, Cabezuelo JB, González C, Lacueva J, Teruel A, Fernández J, Arenas MD. Granulomatous interstitial nephritis associated with hydrochlorothiazide/amiloride. Am J Nephrol. 1995;15(3):270–3. https://doi.org/10.1159/000168845; Yoshikawa H, Watanabe T, Abe T. Tubulo-interstitial nephritis caused by sodium valproate. Brain Dev. 2002;24(2):102–5. https://doi.org/10.1016/s0387-7604(02)00007-4; Tisdale JE, Miller DA, eds. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018.; Derungs A. Medikamentös bedingte akute Nierenschädigung. Ther Umsch. 2015;72(11–12):717–27. https://doi.org/10.1024/0040-5930/a000742; Постников СС, Грацианская АН, Костылева МН. Лекарственные поражения почек. Педиатрия. 2016;95(4):167–73.; Reddy VG. Prevention of postoperative acute renal failure. J Postgrad Med. 2002;48(1):64–70.; Venkataraman R. Can we prevent acute kidney injury? Crit Care Med. 2008;36(4 Suppl.):166–71. https://doi.org/10.1097/ccm.0b013e318168c74a; Stewart J, Findlay G, Smith N, Kelly K, Mason M. Adding Insult to Injury: A Review of the Care of Patients Who Died in Hospital with a Primary Diagnosis of Acute Kidney Injury (Acute Renal Failure). London: NCEPOD; 2009.; Cerda J, Bagga A, Kher V, Chakravarthi R. The contrasting characteristics of acute kidney injury in developed and developing countries. Nat Clin Pract Nephrol. 2008;4(3):138–53. https://doi.org/10.1038/ncpneph0722; Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685–93. https://doi.org/10.1001/archinte.160.5.685; Смирнов АВ, Добронравов ВА, Румянцев АШ, Шилов ЕМ, Ватазин АВ, Каюков ИГ и др. Национальные рекомендации. Острое повреждение почек: основные принципы диагностики, профилактики и терапии. Часть II. Нефрология. 2016;20(2):86–100.; Bidulka P, Fu EL, Leyrat C, Kalogirou F, McAllister KSL, Kingdon EJ, et al. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care. BMC Med. 2020;18(1):195. https://doi.org/10.1186/s12916-020-01659-x; Hsu CY, Liu KD, Yang J, Glidden DV, Tan TC, Pravoverov L, et al. Renin-angiotensin system blockade after acute kidney injury (AKI) and risk of recurrent AKI. Clin J Am Soc Nephrol. 2020;15(1):26–34. https://doi.org/10.2215/CJN.05800519; Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum. 2002;32(3 Suppl 1):33–42. https://doi.org/10.1053/sarh.2002.37216; Graham MG. Acute renal failure related to high-dose celecoxib. Ann Intern Med. 2001;135(1):69–70. https://doi.org/10.7326/0003-4819-135-1-200107030-00038; Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis. 2000;35(5):937–40. https://doi.org/10.1016/s0272-6386(00)70266-6; Евсютина ЕП, Диникина ЮВ, Белогурова МБ, Александрович ЮС. Профилактика токсичности при химиотерапии высокими дозами метотрексата у детей. Педиатр. 2019;10(2):89–98.; Громова ЕГ, Бирюкова ЛС, Джумабаева БТ, Курмуков ИА. Практические рекомендации по коррекции нефротоксичности противоопухолевых препаратов. Злокачественные опухоли. Практические рекомендации RUSSCO. 2020;10(3s2):118–30.; Widemann BC, Schwartz S, Jayaprakash N, Christensen R, Pui CH, Chauhan N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy. 2014;34(5):427–39. https://doi.org/10.1002/phar.1360; Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis. 2015;66(5):857–68. https://doi.org/10.1053/j.ajkd.2015.02.340; Perazella MA, Sprangers B. AKI in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(7):1077–9. https://doi.org/10.2215/CJN.02340219; Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev. 2016;30(3):157–67. https://doi.org/10.1016/j.blre.2015.10.003; Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457–68. https://doi.org/10.2147/ijnrd.s39747; Острая почечная недостаточность лекарственного происхождения. Раздел 1. Обзорная информация. Безопасность лекарств. 2000;(1):31–8. [Acute renal failure of medicinal origin. Section 1. Overview information. Bezopasnost’ lekarstv = Drug Safety. 2000;(1):31–8 (In Russ.)]; Thomas MC. Diuretics, ACE inhibitors and NSAIDs – the triple whammy. Med J Aust. 2000;172(4):184–5. https://doi.org/10.5694/j.1326-5377.2000.tb125548.x; Муравьев ЮВ. Как же назначать фолиевую кислоту при ревматоидном артрите в период лечения метотрексатом? Научно-практическая ревматология. 2013;51(2):201–4.; Cosmai L, Porta C, Foramitti M, Perrone V, Mollica L, Gallieni M, Capasso G. Preventive strategies for acute kidney injury in cancer patients. Clin Kidney J. 2020;14(1):70–83. https://doi.org/10.1093/ckj/sfaa127; Захарова ЕВ, Остроумова ОД. Онконефрология: поражения почек при использовании противоопухолевых препаратов. Обзор литературы – часть 1. Нефрология и диализ. 2020;22(3):383–95.; https://www.risksafety.ru/jour/article/view/228
-
16Academic Journal
Authors: D. A. Sychev, O. D. Ostroumova, A. P. Pereverzev, A. I. Kochetkov, T. M. Ostroumova, M. V. Klepikova, E. Yu. Ebzeeva, Д. А. Сычев, О. Д. Остроумова, А. П. Переверзев, А. И. Кочетков, Т. М. Остроумова, М. В. Клепикова, Е. Ю. Эбзеева
Contributors: The study was performed without external funding., Работа выполнена без спонсорской поддержки.
Source: Safety and Risk of Pharmacotherapy; Том 9, № 1 (2021); 15-24 ; Безопасность и риск фармакотерапии; Том 9, № 1 (2021); 15-24 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2021-9-1
Subject Terms: старческой возраст, drug safety, adverse drug reactions, drug-induced diseases, risk factors, older age, advanced age, лекарственная безопасность, нежелательные лекарственные реакции, лекарственно-индуцированные заболевания, факторы риска, пожилой возраст
File Description: application/pdf
Relation: https://www.risksafety.ru/jour/article/view/209/329; https://www.risksafety.ru/jour/article/downloadSuppFile/209/145; Астахова АВ, Лепахин ВК. Лекарства. Неблагоприятные побочные реакции и контроль безопасности. 2-е изд. М.: Эксмо, 2008.; Сычев ДА, Остроумова ОД, Кочетков АИ, Переверзев АП, Остроумова ТМ, Клепикова МВ и др. Лекарственно-индуцированные заболевания: эпидемиология и актуальность проблемы. Фарматека. 2020;27(5):77–84. https://dx.doi.org/10.18565/pharmateca.2020.5.77-84; Angamo MT, Chalmers L, Curtain CM, Bereznicki LR. Adverse-drug-reaction-related hospitalisations in developed and developing countries: a review of prevalence and contributing factors. Drug Saf. 2016;39(9):847–57. https://doi.org/10.1007/s40264-016-0444-7; Hakkarainen KM, Gyllensten H, Jönsson AK, Andersson Sundell K, Petzold M, Hägg S. Prevalence, nature and potential preventability of adverse drug events — a population-based medical record study of 4970 adults. Br J Clin Pharmacol. 2014;78(1):170– 83. https://doi.org/10.1111/bcp.12314; Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018.; Tandon VR, Khajuria V, Mahajan V, Sharma A, Gillani Z, Mahajan A. Drug-induced diseases (DIDs): An experience of a tertiary care teaching hospital from India. Indian J Med Res. 2015;142(1):33–9. https://doi.org/10.4103/0971-5916.162093 Erratum in: Indian J Med Res. 2016;143(1):123.; Vuppalanchi R, Chalasani N. Risk factors for drug-induced liver disease. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease. 3rd ed. Academic Press; 2013. P. 265–74. https://doi.org/10.1016/b978-0-12-387817-5.00016-9; Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;9:2079–86. https://doi.org/10.2147/CIA.S71178; Ткачева ОН, Переверзев АП, Рунихина НК, Котовская ЮВ. К вопросу о безопасности вакцинации против гриппа пациентов пожилого и старческого возраста. Безопасность и риск фармакотерапии. 2018;6(4):155–61. https://doi.org/10.30895/2312-7821-2018-6-4-155-161; de Almeida AJPO, de Almeida Rezende MS, Dantas SH, deLima Silva S, de Oliveira JCPL, de Lourdes Assunção Araújo de Azevedo F, et al. Unveiling the role of inflammation and oxidative stress on age-related cardiovascular diseases. Oxid Med Cell Longev. 2020;2020:1954398. https://doi.org/10.1155/2020/1954398; Chinta SJ, Woods G, Rane A, Demaria M, Campisi J, Andersen JK. Cellular senescence and the aging brain. Exp Gerontol. 2015;68:3–7. https://doi.org/10.1016/j.exger.2014.09.018; Herrera MD, Mingorance C, Rodríguez-Rodríguez R, Alvarez de Sotomayor M. Endothelial dysfunction and aging: an update. Ageing Res Rev. 2010;9(2):142–52. https://doi.org/10.1016/j.arr.2009.07.002; Tesauro M, Mauriello A, Rovella V, Annicchiarico-Petruzzelli M, Cardillo C, Melino G, Di Daniele N. Arterial ageing: from endothelial dysfunction to vascular calcification. J Intern Med. 2017;281(5):471–82. https://doi.org/10.1111/joim.12605; Trindade M, Oigman W, Fritsch Neves M. Potential role of endothelin in early vascular aging. Curr Hypertens Rev. 2017;13(1):33– 40. https://doi.org/10.2174/1573402113666170414165735; Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W. The role of renin-angiotensin-aldosterone system and its new components in arterial stiffness and vascular aging. High Blood Press Cardiovasc Prev. 2018;25(2):137–45. https://doi.org/10.1007/s40292-018-0252-5; Nusbaum NJ. Aging and sensory senescence. South Med J. 1999;92(3):267–75. https://doi.org/10.1097/00007611-199903000-00002; Loh KY, Ogle J. Age related visual impairment in the elderly. Med J Malaysia. 2004;59(4):562–8, quiz 569.; Hughes SG. Prescribing for the elderly patient: why do we need to exercise caution? Br J Clin Pharmacol. 1998;46(6):531–3. https://doi.org/10.1046/j.1365-2125.1998.00842.x; Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14. https://doi.org/10.1046/j.1365-2125.2003.02007.x; Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76. https://doi.org/10.1080/03602530902722679; Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843– 53. https://doi.org/10.1016/s0531-5565(03)00133-5; Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5(3):263–303. https://doi.org/10.1016/j.amjopharm.2007.10.001; Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S, eds. Hazzard’s geriatric medicine and gerontology. 6 ed. New York: McGraw Hill; 2009.; Trifirò G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab. 2011;12(7):611–20. https://doi.org/10.2174/138920011796504473; Cusack BJ, Vestal RE. Clinical pharmacology: Special considerations in the elderly. In: Calkins E, Davis PJ, Ford AB, eds. Practice of geriatric medicine. Philadelphia: W.B. Saunders Co.; 1986. P. 115–36.; O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8. https://doi.org/10.1093/ageing/afu145; By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94. https://doi.org/10.1111/jgs.15767; Pazan F, Weiss C, Wehling M; FORTA. The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2018;35(1):61–71. https://doi.org/10.1007/s40266-017-0514-2. Erratum in: Drugs Aging. 2018;35(7):677.; Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893–900. https://doi.org/10.1007/s40266-013-0118-4; https://www.risksafety.ru/jour/article/view/209
-
17Academic Journal
Authors: T. M. Ostroumova, O. D. Ostroumova, A. V. Filippova, T. F. Guseva, Т. М. Остроумова, О. Д. Остроумова, А. В. Филиппова, Т. Ф. Гусева
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 2 (2021); 117-122 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 2 (2021); 117-122 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-2
Subject Terms: побочные эффекты, drug-induced hypersomnia, medication, adverse drug reaction, side effects, лекарственно-индуцированная гиперсомния, лекарственные средства, нежелательные лекарственные реакции
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1550/1229; https://nnp.ima-press.net/nnp/article/view/1550/1237; Sateia MJ. International classification of sleep disorders – third edition: highlights and modifications. Chest. 2014 Nov;146(5):1387-94. doi:10.1378/chest.14-0970; Полуэктов МГ. Диагностика и лечение расстройств сна. Москва; 2016. С. 193-7.; Gupta R, Seithikurippu R, Almeneessier A, et al. Hypersomnolence and Traffic Safety. Sleep Med Clin. 2017 Sep;12(3):489-99. doi:10.1016/j.jsmc.2017.03.018. Epub 2017 Jun 8.; Pagel JF. Drug-Induced Hypersomnolence. Sleep Med Clin. 2017 Sep;12(3):383-93. doi:10.1016/j.jsmc.2017.03.011. Epub 2017 Jun 10.; Gastel AV. Drug-Induced Insomnia and Excessive Sleepiness. Sleep Med Clin. 2018 Jun;13(2):147-59. doi:10.1016/j.jsmc.2018.02.001. Epub 2018 Mar 28.; Pagel JF, Pandi-Perumal SR, editors. Primary Care Sleep Medicine: A Practical Guide. New York: Springer; 2014. doi:10.1007/978-1-4939-1185-1; Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2018. 1399 р.; Dauvilliers Y, Buguet A. Hypersomnia. Dialogues Clin Neurosci. 2005;7(4):347-56. doi:10.31887/DCNS.2005.7.4/ydauvilliers; Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000 Apr;59(4):865-89. doi:10.2165/00003495-200059040-00014; Drakatos P, Marples L, Muza R, et al. NREM parasomnias: a treatment approach based upon a retrospective case series of 512 patients. Sleep Med. 2019 Jan;53:181-8. doi:10.1016/j.sleep.2018.03.021. Epub 2018 Apr 10.; Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 2012 Dec 12;12:CD009138. doi:10.1002/14651858.CD009138.pub2; Katona CL, Hunter BN, Bray J. A doubleblind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998 Feb;13(2):100-8. doi:10.1002/(sici)1099-1166(199802)13:23.0.co;2-j; Fagiolini A, Albert U, Ferrando L, et al. A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. Int Clin Psychopharmacol. 2020 May;35(3):137-46. doi:10.1097/YIC.0000000000000304; Rizo C, Deshpande A, Ing A, et al. A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants. J Affect Disord. 2011 Apr;130(1-2):290-3. doi:10.1016/j.jad.2010.07.027. Epub 2010 Aug 12.; Schweitzer PK, Griffin KS. Hypersomnia due to Medication or Substance. In: Reference Module in Neuroscience and Biobehavioral Psychology. Elsevier; 2017. doi:10.1016/b978-0-12-809324-5.01065-8; Crocco EA, Cruz-Ortiz С, Camfield K. Pharmacological Management of Anxiety Disorders in the Elderly. Curr Treat Options Psych. 2017 Mar;4(1):33-46. doi:10.1007/s40501-017-0102-4. Epub 2017 Feb 10.; Miller DD, Pharm D. Atypical Antipsychotics: Sleep, Sedation, and Efficacy. Prim Care Companion. J Clin Psychiatry. 2004;6(Suppl 2):3-7.; Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23. doi:10.1056/NEJMoa051688. Epub 2005 Sep 19.; Elger CE, Stefan H, Mann A, at al. A 24-week multicenter, randomized, doubleblind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res. 2010 Feb;88(2-3):255-63. doi:10.1016/j.eplepsyres.2009.12.003. Epub 2010 Jan 12.; Bonanni E, Galli R, Maestri M, et al. Daytime Sleepiness in Epilepsy Patients Receiving Topiramate Monotherapy. Epilepsia. 2004 Apr;45(4):333-7. doi:10.1111/j.0013-9580.2004.47803.x; Reife R, Pledger G, Wu S. Topiramate as Add-On Therapy: Pooled Analysis of Randomized Controlled Trials in Adults. Epilepsia. 2000;41(S1):66-71. doi:10.1111/j.1528-1157.2000.tb02175.x; Biton V, Krauss G, Vasquez-Santana B, et al. A randomized, doubleblind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia. 2011 Feb;52(2):234-42. doi:10.1111/j.1528-1167.2010.02729.x. Epub 2010 Sep 30.; Нодель МР. Гиперсомния и циркадные нарушения при болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2016;8(4):45-50. doi:10.14412/2074-2711-2016-4-45-50; Левин ОС, Ляшенко ЕА. Нарушения сна при болезни Паркинсона. Фарматека. 2014;10(3):12-9.; Schweitzer PK, Randazzo AC. Drugs that disturb sleep and wakefulness. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th ed. Philadelphia: Elsevier; 2017. P. 480-98.; Rosen G, Harris AK, Liu M, et al. The effects of Dexamethasone on sleep in young children with Acute Lymphoblastic Leukemia. Sleep Med. 2015 Apr;16(4):503-9. doi:10.1016/j.sleep.2014.11.002. Epub 2015 Feb 2.; Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5. doi:10.1093/sleep/14.6.540; Gros P, Videnovic A. Overview of Sleep and Circadian Rhythm Disorders in Parkinson Disease. Clin Geriatr Med. 2020 Feb;36(1):119-30. doi:10.1016/j.cger.2019.09.005. Epub 2019 Sep 6.; Сычев ДА, Остроумова ОД, Переверзев АП и др. Лекарственные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020; (6):113-26. doi:10.18565/pharmateca.2020.6.113-126; Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Greenblatt Clin Pharmacol. 1981 Aug;30(2):239-45. doi:10.1038/clpt.1981.154
-
18Academic Journal
Authors: E. Yu. Ebzeeva, O. D. Ostroumova, S. V. Batyukina, T. M. Ostroumova, A. I. Kochetkov, A. A. Kirichenko, Е. Ю. Эбзеева, О. Д. Остроумова, С. В. Батюкина, Т. М. Остроумова, А. И. Кочетков, А. А. Кириченко
Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 2 (2021); 104-110 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 2 (2021); 104-110 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-2
Subject Terms: нежелательные лекарственные реакции, drug-induced depression, iatrogenic depression, depressogenic drugs, adverse drug reaction, лекарственно-индуцированная депрессия, ятрогенная депрессия, лекарственные средства с депрессогенными эффектами
File Description: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1548/1227; Оганов РГ, Ольбинская ЛИ, Смулевич АБ и др. Депрессии и расстройства депрессивного спектра в общемедицинской практике. Результаты программы КОМПАС. Кардиология. 2004;(1):48-55.; Парфенов ВА. Депрессия в неврологической практике и терапия Паксилом. Атмосфера. Неврология. 2004;(1):43-4.; Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2018. 1399 р.; American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.; Сычев ДА, Жучков АВ, Терещенко ОВ, Иващенко ДВ. Постепенная отмена (депрескрайбинг) бензодиазепиновых транквилизаторов. Неврология, нейропсихиатрия, психосоматика. 2019;11(1):89-95. doi:10.14412/2074-2711-2019-1-89-95; Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA. 2008 Mar 2;299(10):1121-2. doi:10.1001/jama.299.10.1121; Warnock JK, Bundren JC. Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy. Psychopharmacol Bull. 1997;33(2):311-6.; Warnock JK, Bundren JC, Morris DW. Depressive mood symptoms associated with ovarian suppression. Fertil Steril. 2000 Nov;74(5):984-6. doi:10.1016/s0015-0282(00)01607-1; Toren P, Dor J, Mester R, et al. Depression in women treated with a gonadotropin-releasing hormone agonist. Biol Psychol. 1996 Mar 1;39(5):378-82. doi:10.1016/0006-3223(95)00473-4; Steingold KA, Cedars M, Lu JK, et al. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet Gynecol. 1987 Mar;69(3 Pt 1):403-11.; Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992 Jan 4;339(8784):1-15.; Grigg JR. Prednisone mood disorder with associated catatatonia. Geriatr Psychiatry Neurol. Jan-Mar 1989;2(1):41-4. doi:10.1177/089198878900200108; Available from: https://www.drugs.com (accessed:19.05.2020).; Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82. doi:10.1056/NEJMoa020047; Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol. 2001 Oct;45(4):515-9. doi:10.1067/mjd.2001.117730; O'Donnell J. Overview of existing research and information linking isotretinoin (accutane), depression, psychosis, and suicide. Am J Ther. Mar-Apr 2003;10(2):148-59. doi:10.1097/00045391-200303000-00012; Warnock JK, Bundren JC, Morris DW. Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy. Biol Psychiatry. 1998 Mar 15;43(6):464-5. doi:10.1016/s0006-3223(97)00396-x; Тювина НА. Дифференциальная диагностика и лечение депрессивных расстройств у женщин в период климактерия. Неврология, нейропсихиатрия, психосоматика. 2011;3(1):66-71. doi:10.14412/2074-2711-2011-137; Тювина НА, Воронина ЕО, Балабанова ВВ, Гончарова ЕМ. Взаимосвязь и взаимовлияние менструально-генеративной функции и депрессивных расстройств у женщин. Неврология, нейропсихиатрия, психосоматика. 2018;10(2):45-51. doi:10.14412/2074-2711-2018-2-45-51; Patten SB, Williams JV, Love EJ. Self-reported depressive symptoms in association with medication exposures among medical; inpatients: a cross-sectional study. Can J Psychiatry. 1995 Jun;40(5):264-9.; Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005 Dec 1;41(11):1648-53. doi:10.1086/497835. Epub 2005 Oct 19.; Alzoubi KH, Khabour OF, Hassan RE, et al. The effect of genetic polymorphisms of RARA gene on the adverse effects profile of isotretinoin-treated acne patients. Int J Clin Pharmacol Ther. 2013 Aug;51(8):631-40. doi:10.5414/CP201874; Mula M, Trimble MR, Sander JW. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia. 2003 Dec;44(12):1573-7. doi:10.1111/j.0013-9580.2003.19103.x; Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia. 2003 May;44(5):659-63. doi:10.1046/j.1528-1157.2003.05402.x; Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia. 2009 May;50(5):1072-6. doi:10.1111/j.1528-1167.2008.01799.x. Epub 2008 Oct 24.; Galvao-de Almeida A, Quarantini LC, Tartaglioni AG, et al. Serotonin-1A receptor CC genotype is associated with persistent depression related to interferon-alpha in hepatitis C patients. Gen Hosp Psychiatry. May-Jun 2014;36(3):255-60. doi:10.1016/j.genhosppsych.2013.12.007. Epub 2013 Dec 24.; Cozzolongo R, Porcelli P, Cariola F, et al. Serotonin gene polymorphisms and lifetime mood disorders in predicting interferoninduced depression in chronic hepatitis C. J Affect Disord. 2015 Sep 1;183:90-7. doi:10.1016/j.jad.2015.04.056. Epub 2015 May 9.; Kraus MR, Schäfer A, Schöttker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2008 Apr;57(4):531-6. doi:10.1136/gut.2007.131607. Epub 2007 Dec 13.; Cunha ECM, Behrensdorf MF, Bavaresco V, et al. Genotype 1 of hepatitis C virus increases the risk of major despession: a 12 week prospective study. Gen Hosp Psychiatry. Jul-Aug 2015;37(4):283-7. doi:10.1016/j.genhosppsych.2015.03.016. Epub 2015 Mar 31.; Whale R, Fialho R, Rolt M, et al. Psychomotor retardation and vulnerability to interferon alpha induced major depressive disorder: Prospective study of a chronic hepatitis C cohort. J Psychosom Res. 2015 Dec;79(6):640-5. doi:10.1016/j.jpsychores.2015.06.003. Epub 2015 Jun 18.; Hamad T. Relationship between psychotropic drugs and pediatric suicidality: review and evaluation of clinical data. Available from: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065bl-10-TAB08-Hammads-Review.pdf (accessed 2020 May 19).; Yudofsky SC. β-Blockers and Depression: The Clinician's Dilemma. JAMA. 1992 Apr 1;267(13):1826-7. doi:10.1001/jama.1992.03480130142042; Pedrol E, Llibre JM, Tasias M, et al. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. HIV Med. 2015 Nov;16(10):628-34. doi:10.1111/hiv.12298. Epub 2015 Aug 4.; Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa, and depression. Hepatology. 2000 Jun;31(6):1207- 11. doi:10.1053/jhep.2000.7880; Victoroff JI, Benson F, Engel J, et al. Interictal depression in patients with medically intractable complex partial seizures: electroencephalography and cerebral metabolic correlates. Ann Neurol. 1990;28:221.; Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002 Mar;63(3):194-8. doi:10.4088/jcp.v63n0304; Hauser P, Khosla J, Aurora H, et al A prospective study of the incidence and openlabel treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942-7. doi:10.1038/sj.mp.4001119; Chen WC, Lai HC, Su WP, et al. Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: an open-label study. Psychiatry Investig. 2015 Jan;12(1):142-5. doi:10.4306/pi.2015.12.1.142. Epub 2015 Jan 12.; Camacho A, Ng B. Methylphenidate for alpha-interferon induced depression. J Psychopharmacol. 2006 Sep;20(5):687-9. doi:10.1177/0269881106063134. Epub 2006 Mar 13.; Malek-Ahmadi P, Prabhu F. Venlafaxine for treatment of interferon alfa-induced depression. Ann Pharmacother. 2006 Nov;40(11):2075. doi:10.1345/aph.1H133. Epub 2006 Oct 17.; Patten SB. Psychopharmacology for the clinician psychopharmacologie pratique. J Psychiatry Neurosci. 2001 Jan;26(1):66.; Davidson J. Seizures and bupropion: a review. J Clin Psychiatry. 1989 Jul;50(7):256-61.; Lambert MV, Robertson MM. Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia. 1999;40 Suppl 10:S21- 47. doi:10.1111/j.1528-1157.1999.tb00884.x; Sabet-Sharghi F, Hutzler JC. Prophylaxis of steroid-induced psychiatric syndromes. Psychosomatics. Winter 1990;31(1):113-4. doi:10.1016/S0033-3182(90)72233-5; Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001 Mar 29;344(13):961-6. doi:10.1056/NEJM200103293441303; Ehret M, Sobieraj DM. Prevention of interferon-alpha-associated depression with antidepressant medications in patients with hepatitis C virus: a systematic review a nd meta-analysis. Int J Clin Pract. 2014 Feb;68(2):255-61. doi:10.1111/ijcp.12268. Epub 2013 Dec 22.; Hou XJ, Xu JH, Wang J, Yu YY. Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? PLoS One. 2013 Oct 30;8(10):e76799.; Udina M, Hidalgo D, Navines R, et al. Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2014 Oct;75(10):e1113-21. doi:10.4088/JCP.13r08800
-
19Academic Journal
Authors: N. A. Arablinskiy, O. D. Ostroumova, A. V. Filippova, Н. А. Араблинский, О. Д. Остроумова, А. В. Филиппова
Source: Meditsinskiy sovet = Medical Council; № 9 (2021); 114-121 ; Медицинский Совет; № 9 (2021); 114-121 ; 2658-5790 ; 2079-701X
Subject Terms: нежелательные лекарственные реакции, drug-induced pancreatitis, drug-induced diseases, antitumor drugs, antineoplastic drugs, adverse drug reactions, лекарственно-индуцированный острый панкреатит, лекарственно-индуцированные заболевания, противоопухолевые лекарственные средства
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/6255/5669; Johnston D.H., Cornish A.L. Acute Pancreatitis in Patients Receiving Chlorothiazide. JAMA. 1959;170(17):1054–1056. https://doi.org/10.1001/jama.1959.03010170016003.; Zion M.M, Goldberg B., Suzman M.M. Corticotrophin and Cortisone in the Treatment of scleroderma. Q J Med. 1955;24(95):215–227. Available at: https://pubmed.ncbi.nlm.nih.gov/13266985/.; Lee J.K., Enns R. Review of Idiopathic Pancreatitis. World J Gastroenterol. 2007;13(47):6296–6313. https://doi.org/10.3748/wjg.v13.i47.6296.; Lankisch P.G., Droge M., Gottesleben F. Drug Induced Pancreatitis: Incidence and Severity. Gut. 1995:37(4):565–567. https://doi.org/10.1136/gut.37.4.565.; Остроумова О.Д., Качан В.О. Лекарственно-индуцированный панкреатит. Лечебное дело. 2020;(3):14–25. https://doi.org/10.24412/2071-5315-2020-12251.; Kale-Pradhan P.B., Wilhelm S.M. Chapter 39: Pancreatitis. In: Tisdale J.E., Miller D.A. (eds). Drug-Induced Diseases: Prevention, Detection, and Management. Bethesda: American Society of Health-System Pharmacists; 2018, pp. 877–904.; Mallory A, Kern F Jr. Drug-Induced Pancreatitis: A Critical Review. Gastroenterology. 1980 Apr;78(4):813–820. Available at: https://pubmed.ncbi.nlm.nih.gov/6986321/.; Trivedi C.D., Pitchumoni C.S. Drug-Induced Pancreatitis: An Update. J Clin Gastroenterol. 2005;39(8):709–716. https://doi.org/10.1097/01.mcg.0000173929.60115.b4.; Badalov N., Baradarian R., Iswara K., Li J., Steinberg W., Tenner S. DrugInduced Acute Pancreatitis: An Evidence-Based Review. Clin Gastroenterol Hepatol. 2007;5(6):648–661. https://doi.org/10.1016/j.cgh.2006.11.023.; Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A. et al. A Method for Estimating the Probability of Adverse Drug Reactions. Clin Pharmacol Ther. 1981;30(2):239–245. https://doi.org/10.1038/clpt.1981.154.; Сычев Д.А, Остроумова О.Д., Переверзев А.П., Кочетков А.И., Остроумова Т.М., Клепикова М.В. и др. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020;(6):113–126. https://doi.org/10.18565/pharmateca.2020.6.113-126.; Hofmann L., Forschner A., Loquai C., Goldinger S., Zimmer L., Ugurel S. et al. Cutaneous, Gastrointestinal, Hepatic, Endocrine, and Renal Side Effects of Anti-PD-1 Therapy. Eur J Cancer. 2016;60:190–209. https://doi.org/10.1016/j.ejca.2016.02.025.; Ibrahim R.A., Berman D.M., DePril V., Humphrey R.W., Chen T., Messina M. et al. Ipilimumab Safety Profile: Summary of Findings From Completed Trials in Advanced Melanoma. J Clin Oncol. 2011;29(15_Suppl):8583. https://doi.org/10.1200/jco.2011.29.15_suppl.8583.; Weber J.S., Kähler K.C., Hauschild A. Management of Immune-Related Adverse Events and Kinetics of Response with Ipilimumab. J Clin Oncol. 2012;30(21):2691–2697. https://doi.org/10.1200/JCO.2012.41.6750.; Schwaiger T., van den Brandt C., Fitzner B., Zaatreh S., Kraatz F., Dummer A. et al. Autoimmune Pancreatitis in MRL/Mp Mice Is a T Cell-Mediated Disease Responsive to Cyclosporine A and Rapamycin Treatment. Gut. 2014;63(3):494–505. https://doi.org/10.1136/gutjnl-2012-303635.; Clamon G., Patel R., Mott S.L. Pancreatitis Associated with Newer Classes of Antineoplastic Therapies. JCSO. 2017;15(3):e135–e141. https://doi.org/10.12788/jcso.0347.; Sumimoto K., Uchida K., Kusuda T., Mitsuyama T., Sakaguchi Y., Fukui T. et al. The Role of CD19+ CD24high CD38high and CD19+ CD24high CD27+ Regulatory B Cells in Patients with Type 1 Autoimmune Pancreatitis. Pancreatology. 2014;14(3):193–200. https://doi.org/10.1016/j.pan.2014.02.004.; Sevin A., Chen A., Atkinson B. Tyrosine Kinase Inhibitor Induced Pancreatitis. J Oncol Pharm Pract. 2013;19(3):257–260. https://doi.org/10.1177/1078155212457968.; Li M., Srinivas S. Acute Pancreatitis Associated with Sorafenib. South Med J. 2007;100(9):909–911. https://doi.org/10.1097/SMJ.0b013e31813c695d.; Pezzilli R., Corinaldesi R., Morselli-Labate A.M. Tyrosine Kinase Inhibitors and Acute Pancreatitis. JOP. 2010;11(3):291–293. Available at: http://www.serena.unina.it/index.php/jop/article/view/3836/4278.; Ghatalia P., Morgan C.J., Choueiri T.K., Rocha P., Naik G., Sonpavde G. Pancreatitis with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors. Crit Rev Oncol Hematol. 2015;94(1):136–145. https://doi.org/10.1016/j.critrevonc.2014.11.008.; Tirumani S.H., Jagannathan J.P., Shinagare A.B., Kim Kw., Krajewski K.M., Ramaiya N.H. Acute Pancreatitis Associated with Molecular Targeted Therapies: A Retrospective Review of the Clinico-Radiological Features, Management and Outcome. Pancreatology. 2013;13(5):461–467. https://doi.org/10.1016/j.pan.2013.08.001.; Russano M., Vincenzi B., Venditti O., D’Onofrio L., Ratta R., Guida F.M. Pazopanib and Pancreatic Toxicity: A Case Report. BMC Res Notes. 2015;8(1):196. https://doi.org/10.1186/s13104-015-1154-4.; Kawakubo K., Hata H., Kawakami H., Kuwatani M., Kawahata S., Kubo K. Pazopanib-Induced Severe Acute Pancreatitis. Case Rep Oncol. 2015;8(2):356–358. https://doi.org/10.1159/000439124.; Péron J., Khenifer S., Potier V., Vitry T., Pasquet F., Rassat R., Pavic M. Axitinib-Induced Acute Pancreatitis: A Case Report. Anticancer Drugs. 2014;25(4):478–479. https://doi.org/10.1097/CAD.0000000000000076.; Engel T., Justo D., Amitai M., Volchek Y., Mayan H. Nilotinib-Associated Acute Pancreatitis. Ann Pharmacother. 2013;47(1):3. https://doi.org/10.1345/aph.1R334.; Blum K.A., Christian B., Flynn J.M., Jaglowski S.M., Jones J.A., Maddocks K., Byrd J.C. A Phase I Trial of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL). Blood. 2012;120(21):1643. https://doi.org/10.1182/blood.V120.21.1643.1643.; Muluneh B., Buie L.W., Collichio F. Vemurafenib-Associated Pancreatitis: Case Report. Pharmacotherapy. 2013;33(4):43–44. https://doi.org/10.1002/phar.1208.; Larkin J., Del Vecchio M., Ascierto P.A., Krajsova I., Schachter J., Neyns B. et al. Vemurafenib in Patients with BRAF(V600) Mutated Metastatic Melanoma: An open-Label, Multicentre, Safety Study. Lancet Oncol. 2014;15(4):436–444. https://doi.org/10.1016/S1470-2045(14)70051-8.; Varma M.R., Mathew S., Krishnadas D., Vinayakumar K.R. Imatinib-Induced Pancreatitis. Indian J Pharmacol. 2010;42(1):50–52. https://doi.org/10.4103/0253-7613.62407.; Palandri F., Castagnetti F., Soverini S., Poerio A., Gugliotta G., Luatti S. et al. Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated with Nilotinib after Imatinib Failure. Haematologica. 2009;94(12):1758– 1761. https://doi.org/doi:10.3324/haematol.2009.010496.; Cortes J.E., Kantarjian H., Shah N.P., Bixby D., Mauro M.J., Flinn I. et al. Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias. N Engl J Med. 2012;367(22):2075–2088. https://doi.org/10.1056/NEJMoa1205127.; Wang H.H., Tsui J., Wang X.Y., Liu S.S., Li J. Bortezomib-Induced Acute Pancreatitis in a Patient with Multiple Myeloma. Leuk Lymphoma. 2014;55(6):1404–1405. https://doi.org/10.3109/10428194.2013.831850.; Solakoglu T., Akyol P., Guney T., Dilek I., Atalay R., Koseoglu H. et al. Acute Pancreatitis Caused by Bortezomib. Pancreatology. 2013;13(2):189–190. https://doi.org/10.1016/j.pan.2013.01.002.; Elouni B., Ben Salem C., Zamy M., Sakhri J., Bouraoui K., Biour M. Bortezomib-Induced Acute Pancreatitis. JOP. 2010;11(3):275–276.; Solakoglu T., Akar M., Aktan Kosker T., Buyukasik S., Ersoy O. Is Bortezomib a Rare Cause of Acute Pancreatitis? JOP. 2013;14(6):682–683. https://doi.org/10.6092/1590-8577/1927.; Talamo G., Sivik J., Pandey M.K., Mir M.A. Bortezomib-Induced Acute Pancreatitis: Case Report and Review of the Literature. J Oncol Pharm Pract. 2016;22(2):332–334. https://doi.org/10.1177/1078155214563813.; Mihaila R.G. A Possible Rare Complication of Bortezomib Treatment, Acute Pancreatitis. Acta Medica Transilvanica. 2013;2:269–171. Available at http://www.amtsibiu.ro/Arhiva/2013/Nr1-en/Mihaila_pdf.pdf.; Gupta H., Bansal R., Khanna S., Saxena S. An Unusual Complication of Bortezomib Therapy: Acute Pancreatitis. Indian J Nephr. 2014;24(2):135– 136. https://doi.org/10.4103/0971-4065.127928.; Gotoh M., Kitahara T., Sakuta J., Akahane D., Ohyashiki K. Multiple Lipoma with Hyperlipidemia in a Multiple Myeloma Patient Treated with Bortezomib/Dexamethazone. Leuk Res. 2010;34(4):120–121. https://doi.org/10.1016/j.leukres.2009.10.003.; Gozzetti A., Fabbri A., Defina M., Chitarrelli I., Bocchia M. Hyperlipidemia in a myeLoma Patient after Bortezomib Treatment. Leuk Res. 2010;34(9):250. https://doi.org/10.1016/j.leukres.2010.03.025.; Misselwitz B., Goede J.S., Pestalozzi B.C., Schanz U., Seebach J.D. Hyperlipidemic Myeloma: Review of 53 Cases. Ann Hematol. 2010;89(6):569–577. https://doi.org/10.1007/s00277-009-0849-9.; Kortuem K.M., Stewart A.K. Carfilzomib. Blood. 2013;121(6):893–897. https://doi.org/10.1182/blood-2012-10-459883.; Urru S.A., Mariotti E., Carta P., Massidda S., Marcias M., Murru R. et al. Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report. Drugs R D. 2014;14(1):9–11. https://doi.org/10.1007/s40268-014-0036-x.; Gandhi M.D., Evens A.M., Fenske T.S., Hamlin P., Coiffier B., Engert A. et al. Pancreatitis in Patients Treated with Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event. Blood. 2014;123(18):2895–2897. https://doi.org/10.1182/blood-2014-03-561878.; Truven Health Analytics. Micromedex® Clinical Knowledge Suite. Micromedex Solutions. User Guide. 2017. Available at: https://www.periodicos.capes.gov.br/images/documents/Micromedex%20UserGuide.pdf.; Haber C.J., Meltzer S.J., Present D.H., Korelitz B.I. Nature and Course of Pancreatitis Caused by 6-Mercaptopurine in the Treatment of Inflammatory Bowel Disease. Gastroenterology. 1986;91(4):982–986. https://doi.org/10.1016/0016-5085(86)90703-1.; Herskowitz L.J., Olansky S., Lang P.G. Acute Pancreatitis Associated with Long-Term Azathioprine Therapy. Occurrence in a Patient with Systemic Lupus Erythematosus. Arch Dermatol. 1979;115(2):179. http://doi.org/10.1001/archderm.1979.04010020025009.; Sturdevant R.A., Singleton J.W., Deren J.L., Law D.H., McCleery J.L. AzathioprineRelated Pancreatitis in Patients with Crohn’s Disease. Gastroenterology. 1979;77(4/2):883–886. Available at: https://pubmed.ncbi.nlm.nih.gov/38178/; Kawanishi H., Rudolph E., Bull F.E. Azathioprine-Induced Acute Pancreatitis. N Engl J Med. 1973;289(7):357. https://doi.org/10.1056/NEJM197308162890708.; Paloyan D., Levin B., Simonowitz D. Azathioprine-Associated Acute Pancreatitis. Am J Dig Dis. 1977;22(9):839–840. https://doi.org/10.1007/BF01694518.; Niederle B., Bartos V., Hrodek O., Hyniová H. Acute Pancreatitis after Imuran in a Patient with Autoimmune Haemolytic Anaemia. Mater Med Pol. 1978;10(1):60–62. Available at: https://pubmed.ncbi.nlm.nih.gov/642594/.; Simons-Ling N., Schachner L., Penneys N., Gorman H., Zillereulo G., Strauss J. Childhood Systemic Lupus Erythematosus. Association with Pancreatitis, Subcutaneous Fat Necrosis, and Calcinosis Cutis. Arch Dermatol. 1983;119(6):491–494. https://doi.org/10.1001/archderm.119.6.491.; Tragnone A., Bazzocchi G., Aversa G., Pecorelli M.G., Elmi G., Venerato S., Lanfranchi G.A. Acute Pancreatitis after Azathioprine Treatment for Ulcerative Colitis. Ital J Gastroenterol. 1996;28(2):102–104. Available at: https://pubmed.ncbi.nlm.nih.gov/8782004/.; Siwach V., Bansal V., Kumar A., Rao Ch U., Sharma A., Minz M. Post-Renal Transplant Azathioprine-Induced Pancreatitis. Nephrol Dial Transplant. 1999;14(10):2495–2498. https://doi.org/10.1093/ndt/14.10.2495.; Castiglione F., Del Vecchio Blanco G., Rispo A., Mazzacca G. Prevention of Pancreatitis by Weekly Amylase Assay in Patients with Crohn’s Disease Treated with Azathioprine. Am J Gastroenterol. 2000;95(9):2394–2395. https://doi.org/10.1111/j.1572-0241.2000.02347.x.; Toubanakis C., Batziou E., Sipsas N., Galanopoulos G., Tzivras M., Archimandritis A. Acute Pancreatitis after Long-Term Therapy with Mesalazine, and Hyperamylasaemia Associated with Azathioprine in a Patient with Ulcerative Colitis. Eur J Gastroenterol Hepatol. 2003;15(8):933–934. https://doi.org/10.1097/00042737-200308000-00019.; Floyd A., Pedersen L., Nielsen G.L., Thorlacius-Ussing O., Sorensen H.T. Risk of Acute Pancreatitis in Users of Azathioprine: A Population-Based CaseControl Study. Am J Gastroenterol. 2003;98(6):1305–1308. https://doi.org/10.1111/j.1572-0241.2003.07459.x.; Bank L., Wright J.P. 6-Mercaptopurine-Related Pancreatitis in 2 Patients with Inflammatory Bowel Disease. Dig Dis Sci. 1984;29(4):357–359. https://doi.org/10.1007/BF01318523.; Willert J.R., Dahl G.V., Marina N.M. Recurrent Mercaptopurine-Induced Acute Pancreatitis: A Rare Complication of Chemotherapy for Acute Lymphoblastic Leukemia in Children. Med Pediatr Oncol. 2002;38(1):73–74. https://doi.org/10.1002/mpo.1273.; Weersma R.K., Peters F.T., Oostenbrug L.E., van den Berg A.P., van Haastert M., Ploeg R.J. et al. Increased Incidence of Azathioprine-Induced Pancreatitis in Crohn’s Disease Compared with Other Diseases. Aliment Pharmacol Ther. 2004;20(8):843–850. https://doi.org/10.1111/j.1365-2036.2004.02197.x.; Nogueira J.R., Freedman M.A. Acute Pancreatitis as a Complication of Imuran Therapy in Regional Enteritis. Gastroenterology. 1972;62(5):1040– 1041. Available at: https://pubmed.ncbi.nlm.nih.gov/5029069/.; Lai S.W., Wang Y.C., Wang C.H., Huang T.Y. Acute Pancreatitis and Erythema Nodosum Associated with Azathioprine. QJM. 2012;105(4):363–364. https://doi.org/10.1093/qjmed/hcr041.; Halalsheh H., Bazzeh F., Alkayed K., Salami K., Madanat F. 6-MercaptopurineInduced Recurrent Acute Pancreatitis in Children with Acute Lymphoblastic Leukemia/Lymphoma. J Pediatr Hematol Oncol. 2013;35(6):470–472. https://doi.org/10.1097/MPH.0b013e318271c92f.; Chaparro M., Ordas I., Cabre E., Garcia-Sanchez V., Bastida G., Penalva M. et al. Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Longterm Follow-up Study of 3931 Patients. IBD. 2013;19(7):1404–1410. https://doi.org/10.1097/MIB.0b013e318281f28f.; Weetman R.M., Baehner R.L. Latent Onset of Clinical Pancreatitis in Children Receiving L-Asparaginase Therapy. Cancer. 1974;34(3):780–785. https://doi.org/10.1002/1097-0142(197409)34:33.0.co;2-u.; Haskell C.M., Canellos G.P., Leventhal B.G., Carbone P.P., Block J.B., Serpick A.A., Selawry O.S. L-Asparaginase: Therapeutic and Toxic Effects in Patients with Neoplastic Disease. N Engl J Med. 1969;281(19):1028– 1034. https://doi.org/10.1056/NEJM196911062811902.; Land V.J., Sutow W.W., Fernbach D.J., Lane D.M., Williams T.E. Toxicity of L-Asparginase in Children with Advanced Leukemia. Cancer. 1972;30(2):339–347. https://doi.org/10.1002/1097-0142(197208)30:23.0.co;2-p.; Raja R.A., Schmiegelow K., Albertsen B.K., Prunsild K., Zeller B., Vaitkeviciene G. et al. Asparaginase-Associated Pancreatitis in Children with Acute Lymphoblastic Leukaemia in the NOPHO ALL2008 Protocol. Br J Haematol. 2014;165(1):126–133. https://doi.org/10.1111/bjh.12733.; Greenstein R., Nogeire C., Ohnuma T., Greenstein A. Management of Asparaginase Induced Hemorrhagic Pancreatitis Complicated by Pseudocyst. Cancer. 1979;43(2):718–722. https://doi.org/10.1002/1097-0142(197902)43:23.0.co;2-r.; Holland J.F., Bast R.C. Jr, Morton D.L., Frei E. III, Kufe D.W., Weichselbaum R.R. (eds). Cancer Medicine. 4th ed. Baltimore: Williams & Wilkins, 1997. Vol. I, 1800 pp., Vol. II, 1800 pp.; Pratt C.B., Simone J.V., Zee P., Aur R.J., Johnson W.W. Comparison of Daily versus Weekly L-Asparaginase for the Treatment of Childhood Acute Leukemia. J Pediatr. 1970;77(3):474–483. https://doi.org/10.1016/s0022-3476(70)80023-3.; Shaw M.T., Barnes C.C., Madden F.J., Bagshawe K.D. L-Asparaginase and Pancreatitis. Lancet. 1970;2(7675):721. https://doi.org/10.1016/s0140-6736(70)91990-2.; Tan C.L., Chiang S.P., Wee K.P. Acute Haemorrhagic Pancreatitis Following L-Asparaginase Therapy in Acute Lymphoblastic Leukaemia – A Case Report. Singapore Med J. 1974;15(4):278–282. Available at: https://pubmed.ncbi.nlm.nih.gov/4533158/.; Koniver G.A., Scott J.E. Pancreatitis with Pseudocyst: A Complication of L-Asparaqinase Therapy for Leukemia. Del Med J. 1978;50(6):330–332. Available at: https://pubmed.ncbi.nlm.nih.gov/668953/.; Jain R., Ramanan S.V. Iatrogenic Pancreatitis. A Fatal Complication in the Induction Therapy for Acute Lymphocytic Leukemia. Arch Intern Med. 1978;138(11):1726. https://doi.org/10.1001/archinte.138.11.1726.; Yang C.M., Hsieh Y.L., Hwang B. Acute Pancreatitis in Association with L-Asparaginase Therapy: Report of One Case. Zhonghua Yi Xue Za Zhi (Taipei). 1993;51(1):74–77. Available at: https://pubmed.ncbi.nlm.nih.gov/8384060/.; Sadoff J., Hwang S., Rosenfeld D., Ettinger L., Spigland N. Surgical Pancreatic Complications Induced by L-Asparaginase. J Pediatr Surg. 1997;32(6):860–863. https://doi.org/10.1016/s0022-3468(97)90636-9.; Cheung Y.F., Lee C.W., Chan C.F., Chan K.L., Lau Y.L., Yeung C.Y. Somatostatin Therapy in L-Asparaginase-Induced Pancreatitis. Med Pediatr Oncol. 1994;22(6):421–424. https://doi.org/10.1002/mpo.2950220614.; Sahu S., Saika S., Pai S.K., Advani S.H. L-Asparaginase (Leunase) Induced Pancreatitis in Childhood Acute Lymphoblastic Leukemia. Pediatr Hematol Oncol. 1998;15(6):533–538. https://doi.org/10.3109/08880019809018315.; Garrington T., Bensard D., Ingram J.D., Silliman C.C. Successful Management with Octreotide of a Child with L-Asparaginase Induced Hemorrhagic Pancreatitis. Med Pediatr Oncol. 1998;30(2):106–109. https://doi.org/10.1002/(sici)1096-911x(199802)30:23.0.co;2-m.; Hsu Y.J., Chen Y.C., Ho C.L., Kao W.Y., Chao T.Y. Diabetic Ketoacidosis and Persistent Hyperglycemia as Long-Term Complications of L-AsparaginaseInduced Pancreatitis. Zhonghua Yi Xue Za Zhi (Taipei). 2002;65(9):441–445. Available at: https://pubmed.ncbi.nlm.nih.gov/12433031/.; Iatrogenic pancreatitis. Br Med J. 1977;2(6094):1043. https://doi.org/10.1136/bmj.2.6094.1043.; Jaffe N., Traggis D., Das L., Kim B.S., Won H., Hann L. et al. Comparison of Daily and Twice-Weekly Schedule of L-Asparaginase in Childhood Leukemia. Pediatrics. 1972;49(4):590–595. Available at: https://pediatrics.aappublications.org/content/49/4/590.long.; Larsen C.C., Laursen C.B., Dalby K., Graumann O. Splenic Artery Pseudoaneurysm Due to Acute Pancreatitis in a 6-Year-Old boy with Acute Lymphoblastic Leukaemia Treated with L-Aspariginase. BMJ Case Rep. 2014;bcr2013202298. https://doi.org/10.1136/bcr-2013-202298.; Treepongkaruna S., Thongpak N., Pakakasama S., Pienvichit P., Sirachainan N., Hongeng S. Acute Pancreatitis in Children with Acute Lymphoblastic Leukemia after Chemotherapy. J Pediatr Hematol Oncol. 2009;31(11):812–815. https://doi.org/10.1097/MPH.0b013e3181b87035.; Flores-Calderón J., Exiga-Gonzaléz E., Morán-Villota S., Martín-Trejo J., Yamamoto-Nagano A. Acute Pancreatitis in Children with Acute Lymphoblastic Leukemia Treated with L-Asparaginase. J Pediatr Hematol Oncol. 2009;31(10):790–793. https://doi.org/10.1097/MPH.0b013e3181b794e8.; Kearney S.L., Dahlberg S.E., Levy D.E., Voss S.D., Sallan S.E., Silverman L.B. Clinical Course and Outcome in Children with Acute Lymphoblastic Leukemia and Asparaginase-Associated Pancreatitis. Pediatr Blood Cancer. 2009;53(2):162–167. https://doi.org/10.1002/pbc.22076.; Oettgen H.F., Stephenson P.A., Schwartz M.K., Leeper R.D., Tallai L., Tan C.C. et al. Toxicity of E. coli L-Asparaginase in Man. Cancer. 1970;25(2):253–278. https://doi.org/10.1002/1097-0142(197002)25:23.0.co;2-u.; Zubrod C.G. The Clinical Toxicities of L-Asparaginase in Treatment of Leukemia and Lymphoma. Pediatrics. 1970;45(4):555–559. Available at: https://pediatrics.aappublications.org/content/45/4/555.long.; Whitecar J.P. Jr, Bodey G.P., Harris J.E, Freireich E.J. L-Asparaginase. N Engl J Med. 1970;282(13):732–734. https://doi.org/10.1056/NEJM197003262821307.; Dolowy W.C., Henson D., Cornet J., Sellin H. Toxic and Antineoplastic Effects of L-Asparaginase. Study of Mice with Lymphoma and Normal Monkeys and Report on a Child with Leukemia. Cancer. 1966;19(12):1813–1819. https://doi.org/10.1002/1097-0142(196612)19:123.0.co;2-e.; Earl M. Incidence and Management of Asparaginase-Associated Adverse Events in Patients with Acute Lymphoblastic Leukemia. Clin Adv Hematol Oncol. 2009;7(9):600–606. Available at: https://pubmed.ncbi.nlm.nih.gov/20020672/.; McBride C.E., Yavorski R.T., Moses F.M., Robson M.E., Solimando D.A. Jr., Byrd J.C. Acute Pancreatitis Associated with Continuous Infusion Cytarabine Therapy: A Case Report. Cancer. 1996;77(12):2588–2591. https://doi.org/10.1002/(SICI)1097-0142(19960615)77:123.0.CO;2-N.; Izraeli S., Adamson P.C., Blaney S.M., Balis F.M. Acute Pancreatitis after Ifosfamide Therapy. Cancer. 1994;74(5):1627–1628. https://doi.org/10.1002/1097-0142(19940901)74:53.0.co;2-u.; Puckett J.B., Butler W.M., McFarland J.A. Pancreatitis and Cancer Chemotherapy. Ann Intern Med. 1982;97(3):453. https://doi.org/10.7326/0003-4819-97-3-453_1.; Altman A.J., Dinndorf P., Quinn J.J. Acute Pancreatitis in Association with Cytosine Arabinoside Therapy. Cancer. 1982;49(7):1384–1386. https://doi.org/10.1002/1097-0142(19820401)49:73.0.co;2-6.; Newman C.E, Ellis D.J. Pancreatitis during Combination Chemotherapy. Clin Oncol. 1979;5(1):83–84. Available at: https://pubmed.ncbi.nlm.nih.gov/421389/; Siemers R.F., Friedenberg W.R., Norfleet R.G. High-Dose Cytosine Arabinoside-Associated Pancreatitis. Cancer. 1985;56(8):1940–1942. https://doi.org/10.1002/1097-0142(19851015)56:83.0.co;2-n.; McGrail L.H., Sehn L.H., Weiss R.B., Robson M.R., Antin J.H., Byrd J.C. Pancreatitis during Therapy of Acute Myeloid Leukemia: Cytarabine Related? Ann Oncol. 1999;10(11):1373–1376. https://doi.org/10.1023/a:1008342320532.; Calvo D.B. 3rd, Patt Y.Z., Wallace S., Chuang V.P., Benjamin R.S., Pritchard J.D. et al. Phase I-II Trial of Percutaneous Intra-Arterial Cis-Diamminedichloro Platinum (II) for Regionally Confined Malignancy. Cancer. 1980;45(6):1278– 1283. https://doi.org/10.1002/1097-0142(19800315)45:63.0.co;2-i.; Bunin N., Meyer W.H., Christensen M., Pratt C.B. Pancreatitis Following Cisplatin: A Case Report. Cancer Treat Rep. 1985;69(2):236–237. Available at: https://pubmed.ncbi.nlm.nih.gov/3855700/.; Stewart D.J., Feun L.G., Maor M., Leavens M., Burgess M.A., Benjamin R.S., Bodey G.P. Sr. Weekly Cisplatin during Cranial Irradiation for Malignant Melanoma Metastatic to Brain. J Neurooncol. 1983;1(1):49–51. https://doi.org/10.1007/BF00153641.; Socinski M.A., Garnick M.B. Acute Pancreatitis Associated with Chemotherapy for Germ Cell Tumors in Two Patients. Ann Intern Med. 1988;108(4):567–568. https://doi.org/10.7326/0003-4819-108-4-567.; Yeung K.Y., Haidak D.J., Brown J.A., Anderson D. Metastasis-Induced Acute Pancreatitis in Small Cell Bronchogenic Carcinoma. Arch Intern Med. 1979;139(5):552–554. http://doi.org/10.1001/archinte.1979.03630420042014.; Spiegel R.J., Magrath I.T. Tumor Lysis Pancreatitis. Med Pediatr Oncol. 1979;7(2):169–172. https://doi.org/10.1002/mpo.2950070210.; Nevalainen T.J. Cytotoxicity of Vinblastine and Vincristine to Pancreatic Acinar Cells. Virchows Arch B Cell Pathol. 1975;18(2):119–127. https://doi.org/10.1007/BF02889240.; Ben Kridis W., Khanfir A., Frikha M. Acute Pancreatitis Induced by Anticancer Chemotherapy. Acta Clin Belg. 2013;68(4):309–310. https://doi.org/10.2143/ACB.3351.; Garg R., Agarwala S., Bhatnagar V. Acute Pancreatitis Induced by Ifosfamide Therapy. J Pediatr Surg. 2010;45(10):2071–2073. https://doi.org/10.1016/j.jpedsurg.2010.07.028.; Kumar D.M., Sundar S., Vasanthan S. A Case of Paclitaxel-Induced Pancreatitis. Clin Oncol (R Coll Radiol). 2003;15(1):35. https://doi.org/10.1053/clon.2002.0170.; Hoff P.M., Valero V., Holmes F.A., Whealin H., Hudis C., Hortobagyi G.N. Paclitaxel-Induced Pancreatitis: A Case Report. J Natl Cancer Inst. 1997;89(1):91–93. https://doi.org/10.1093/jnci/89.1.91.; Hudis C., Riccio L., Holmes F., Seidman A., Baselga J., Currie V. et al. Phase II Study of Semisynthetic Paclitaxel in Metastatic Breast Cancer. Eur J Cancer. 1997;33(13):2198–2202. https://doi.org/10.1016/s0959-8049(97)00254-2.; Butt W., Saadati H., Saif M.W. Oxaliplatin-Induced Pancreatitis: A Case Series. Anticancer Res. 2010;30(12):5113–5115. Available at: https://ar.iiarjournals.org/content/30/12/5113.long.; Chan H.Y., Ng C.M., Tiu S.C., Chan A.O., Shek C.C. Hypertriglyceridaemia-Induced Pancreatitis: A Contributory Role of Capecitabine? Hong Kong Med J. 2012;18(6): 526–529. Available at: https://www.hkmj.org/system/files/hkm1212p526.pdf.; Yucel H., Warmerdam L.V. Capecitabine-Induced Pancreatitis. J Oncol Pharm Pract. 2010;16(2):133–134. https://doi.org/10.1177/1078155209344650.; Jones K.L., Valero V. Capecitabine-Induced Pancreatitis. Pharmacotherapy. 2003;23(8):1076–1078. https://doi.org/10.1592/phco.23.8.1076.32870.; Gurzu S., Jung I., Comsulea M., Kadar Z., Azamfirei L., Molnar C. Lethal Cardiotoxicity, Steatohepatitis, Chronic Pancreatitis, and Acute Enteritis Induced by Capecitabine and Oxaliplatin in a 36-Year-Old Woman. Diagn Pathol. 2013;8:150. https://doi.org/10.1186/1746-1596-8-150.; Singh V., Devata S., Cheng Y.C. Carboplatin and Docetaxel-Induced Acute Pancreatitis: Brief Report. Int J Clin Oncol. 2010;15(6):642–644. https://doi.org/10.1007/s10147-010-0105-2.; Sakhri J., Ben Salem C., Harbi H., Fathallah N., Ltaief R. Severe Acute Pancreatitis due to Tamoxifen-Induced Hypertriglyceridemia with Positive Rechallenge. JOP. 20105;11(4):382–384. Available at: http://www.serena.unina.it/index.php/jop/article/view/3626/3965.; Alagozlu H., Cindoruk M., Unal S. Tamoxifen-Induced Severe Hypertriglyceridaemia and Acute Pancreatitis. Clin Drug Investig. 2006;26(5):297–302. https://doi.org/10.2165/00044011-200626050-00007.; Lin H.H., Hsu C.H., Chao Y.C. Tamoxifen-Induced Severe Acute Pancreatitis: A Case Report. Dig Dis Sci. 2004;49(6):997–999. https://doi.org/10.1023/b:ddas.0000034561.37401.f2.; Athyros V.G., Giouleme O.I., Nikolaidis N.L., Vasiliadis T.V., Bouloukos V.I., Kontopoulos A.G., Eugenidis N.P. Long-Term Follow-Up of Patients with Acute Hypertriglyceridemia-Induced Pancreatitis. J Clin Gastroenterol. 2002;34(4):472–475. https://doi.org/10.1097/00004836-200204000-00020.; Artac M., Sari R., Altunbas H., Karayalcin U. Asymptomatic Acute Pancreatitis due to Tamoxifen-Induced Severe Hypertriglyceridemia in a Patient with Diabetes Mellitus and Breast Cancer. J Chemother. 2002;14(3):309–311. https://doi.org/10.1179/joc.2002.14.3.309.; Elisaf M.S., Nakou K., Liamis G., Pavlidis N.A. Tamoxifen-Induced Severe Hypertriglyceridemia and Pancreatitis. Ann Oncol. 2000;11(8):1067–1069. https://doi.org/10.1023/a:1008309613082.; Colls B.M., George P.M. Severe Hypertriglyceridaemia and Hypercholesterol aemia Associated with Tamoxifen Use. Clin Oncol (R Coll Radiol). 1998;10(4):270–271. https://doi.org/10.1016/s0936-6555(98)80019-8.; Noguchi M., Taniya T., Tajiri K., Miwa K., Miyazaki I., Koshino H. et al. Fatal Hyperlipaemia in a Case of Metastatic Breast Cancer Treated by Tamoxifen. Br J Surg. 1987;74(7):586–587. https://doi.org/10.1002/bjs.1800740714.
-
20Academic Journal
Authors: Asoskova A.V., Sychev D.A., Kubanov A.A.
Contributors: 1
Source: Annals of the Russian academy of medical sciences; Vol 76, No 3 (2021); 254-267 ; Вестник Российской академии медицинских наук; Vol 76, No 3 (2021); 254-267 ; 2414-3545 ; 0869-6047 ; 10.15690/vramn.763
Subject Terms: psoriasis, psoriatic arthritis, methotrexate, pharmacogenetics, adverse drug reactions, methotrexate toxicity, patient safety, псориаз, псориатический артрит, метотрексат, фармакогенетика, нежелательные лекарственные реакции, токсичность метотрексата, безопасность пациентов
File Description: application/pdf
Relation: https://vestnikramn.spr-journal.ru/jour/article/view/1527/1466; https://vestnikramn.spr-journal.ru/jour/article/view/1527/1477; https://vestnikramn.spr-journal.ru/jour/article/downloadSuppFile/1527/1956